Archive Uncategorized

Uncategorized

$ETST Focuses on Completing Key Projects in 2018 – CannabisNewsBreaks

February 7, 2018

Goal is to raise $4 million to help company finance its planned projects
Expansion into Canada eyed, attorney retained to help seek Canadian licenses to import ETST’s CBD-rich hemp oil into country
ETST would also use funding for MSN-2, its home kit for the detection of sexually transmitted diseases

Earth Science Tech, Inc. (OTC: ETST) is working toward an uplisting to the OTCQB Venture Market in early 2018. It has also retained counsel for a planned Regulation A+ Tier 2 round of financing, which the company hopes will raise an aggregate of $4 million (http://cnw.fm/W8I2d). The funds would be used to finance its planned projects in the new year and for general working capital (http://cnw.fm/Pi0hl), with share cancellation by company founders counteracting dilution.

ETST is also eyeing expansion into Canada in 2018, and it has appointed an attorney who will serve as consultant for ETST’s activities in that country, Avi Levi, Esq. (http://cnw.fm/aW8ww). He will help the company apply for licenses to import its CBD-rich hemp oil into Canada. It will then be exported to various countries as raw hemp oil or in individual ready-to-consume bottles, the company said.

Dr. Michel Aube, CEO and chief scientific officer of the company, said, “With the funds being raised through the Regulation A+ offering, we will be in a position to begin finalizing all of our projects while we pursue grants from the Canadian government to cover our MSN-2 medical device, CBD patent pending formulas and CBD based generic pharmaceutical drugs.”

The MSN-2 device is prepared for third-party evaluation ahead of manufacture and commercialization. The MSN-2 device is a home kit designed for the detection of sexually transmitted diseases.

ETST is a biotechnology company operating in the fields of hemp cannabinoid pharmaceutical, nutraceutical, and medical device R&D. Its hemp CBD is made using the liquid extraction process. As a result, its CBD oil is 100 percent natural and organic, as noted by the company.

ETST has three wholly owned subsidiaries. First, Earth Science Pharma, Inc. specializes in the development of medical devices for the treatment of sexually transmitted diseases. Second, Cannabis Therapeutics, Inc. works to explore the medicinal powers of CBD. Cannabis Therapeutics holds a provisional application patent for a CBD product which develops treatments for ovarian and breast cancers. Third, KannaBidioid, Inc. focuses on the recreational cannabis space.

For more information, visit the company’s website at www.EarthScienceTech.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Monday, February 26th, 2018 Uncategorized Comments Off

$PVOTF Advances #CBD Therapy Delivery Options

February 26, 2018

Forecasts envision medical cannabis market reaching $55.8 billion by 2025
PVOTF filing patents for smoked, transdermal and mucosal delivery of therapeutics
Global partnerships and acquisitions open windows of opportunity for company

With its recently announced plan to acquire Agro-Biotech, a Québec-based ACMPR Canadian licensed cannabis producer (http://cnw.fm/WPwl2), Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) has raised the bar in the race to capture part of the booming medical cannabis market, which is expected to reach over $55 billion by 2025. Agro-Biotech, which operates a fully-licensed indoor hydroponic cannabis production facility that’s able to turn out 10,000 kilograms per year, gives Pivot Pharmaceuticals a unique vertically-integrated position in the industry. Pivot is already known for its advanced patent-backed CBD therapy delivery options, and delivery technology has become a hot button in the burgeoning marijuana market.

Amid the flurry of activity surrounding the rush to provide medical marijuana therapies in markets where it is newly legalized, one lingering question regulators and industry insiders continue to grapple with is how to best administer cannabis to patients seeking relief from muscle spasms, pain, anxiety and other disorders. Pivot Pharmaceuticals is evaluating and preparing to market a variety of drug delivery technologies that can help the assimilation of cannabinoids for such human and veterinary patients.

Pivot has identified an area of need within the industry as efforts to provide clinical data for cannabis’s purported benefits strive to establish a scientific credence to what has been a largely word-of-mouth substantiation of the drug. Decades of recreational use, mostly in smoking marijuana, as well as historical research into cannabis’s ancient therapeutic uses, have given rise to the newly popular movement to establish clinical uses for the plant as governmental recognition has spread across the United States and Canada, as well as in some other countries across the globe.

As part of that movement, some companies are searching for alternatives to smoking the plant, not only to avoid the image of casual and medically unregulated recreational drug use but also out of concern for patients’ health and the interests of non-patients who may be offended by the smoke. Pivot has filed three provisional patents targeting different cannabinoid delivery methods. One anticipates inhalation for delivery of the therapeutics, another promotes transdermal passage through the skin using patches and creams, and a third prefers topical delivery through mucus in the buccal, nasal, vaginal and anal areas using a gel, mouthwash or suppository (http://cnw.fm/qT4N3).

The British Columbia, Canada-based company’s agreement with Germany’s Solmic Research GmbH has given Pivot worldwide rights to the Solmic Solubilisation technology underpinning a water-soluble oral solution that Pivot has made ready for market. A partnership with Israel’s Solubest Ltd. has resulted in a semi-solid cream that is currently in the stability evaluation phase of development, and Pivot’s anticipated February 28 closing on its option to acquire 100 percent of North Carolina’s Thrudermic, LLC has already led to the commencement of development of a product using Thrudermic’s transdermal nanotechnology for a systemic cannabidiol (CBD) product. Access to Israeli labs licensed to work with CBD and its more intoxicating cannabis sibling tetrahydrocannabinol (THC) gives Pivot an edge in research and development.

Pivot is also scheduled to close on its acquisition of California’s ERS Holdings, LLC on February 28, which has a patented ready-to-infuse cannabis (“RTIC”) oil-to-powder technology that Pivot expects to monetize by entering the cannabis-infused beverage market, particularly in the alcohol beverage industry, where Pivot has already identified potential partners as beverage companies battle the possibility of legal marijuana eating into beer sales (http://cnw.fm/AdR47). The company also expects to use RTIC technology for wellness products such as over-the-counter sleep aids and cough medications.

As legalization has spread for cannabis’s medical applications, market forecasts have grown, and the therapeutic product derivatives of the plant are expected to fuel a $55.8 billion market by 2025, according to a 2017 report by Grand View Research (http://cnw.fm/98vNG). Pivot’s first Solmic-enabled oral product, PGS-N001, is designed to provide relief to patients suffering from chemotherapy-induced vomiting, nausea, neutropenia and anemia — major side effects from cancer treatment that often lead to the premature discontinuation of the treatment. Of the 14 million new cancer diagnoses identified by the National Cancer Institute in 2012, about four million of them were expected to lead to chemotherapy treatment, and chemotherapy-induced nausea and vomiting (“CINV”) affects an estimated 70 to 80 percent of patients undergoing chemotherapy, according to Transparency Market Research (http://cnw.fm/8RC0y), fueling a cancer supportive care products market that’s expected to reach $29.87 billion by 2021.

Pivot intends to register PGS-N001 as a natural health product for consumers and follow it with other products that will have a shorter development cycle as they follow the natural health product pathway.

“Solmic’s water-soluble technology has already been demonstrated in the nutraceutical and cosmeceutical markets in Europe,” Pivot CEO Patrick Frankham stated in a news release. “The addition of Solmic, our second disruptive drug delivery technology platform for cannabinoids, strengthens our business strategy to be a market leader in the development and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products.”

For more information, visit the company’s website at www.PivotPharma.com

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Monday, February 26th, 2018 Uncategorized Comments Off

$DJACF Among the Key Companies That Will Remap Canada’s Cannabis Retail Industry

February 23, 2018

CannabisNewsWire Editorial Coverage: Out of 120 applicants, Manitoba recently awarded four master retail licenses, a monumental action as Canada prepares to legalize cannabis for recreational use this summer. The entities that now hold prized licenses to retail pot and its associated paraphernalia in the province are: Tokyo Smoke, a subsidiary of HIKU Brands (CSE:HIKU; OTCBB: DJACF) (DJACF Profile); a consortium of Delta 9 Cannabis Inc. and Canopy Growth Corp. (TSX: WEED) (OTC: TWMJF); National Access Cannabis (CSE: NAC) (OTC: NACNF); and 10552763 Canada Corporation. One key industry player that missed out on this licensing opportunity is MedReleaf (TSE: LEAF) (OTC: MEDFF). These licenses open the doors to considerable recreational retail revenue potential, and investors with foresight were quick to take action, with Aphria (TSX: APH) (OTC: APHQF) and Koicha Partners LP investing millions into the big four’s newest presence, HIKU.

New name, established brand

Although the name HIKU is new, the brands behind it are well-known and have interesting back stories. Tokyo Smoke was named “best brand” at the inaugural Cannabis Industry Awards in December 2017, and in January 2018 the company joined forces with Doja Cannabis Company to create HIKU. HIKU is led by CEO Alan Gertner and President Trent Kitsch, who founded the best-selling men’s brand, SAXX Underwear.

Gertner ran a $100 million business as head of an Asia-Pacific-wide sales team during his tenure in corporate strategy at Google. When he found that what he thought was his dream job was less than fulfilling, he shifted gears and co-founded Tokyo Smoke with his father Lorne Gertner, formerly PharmaCan chairman (now Cronos Group), who was dubbed the ‘Godfather of Canadian Cannabis’.

Tokyo Smoke is a seasoned retailer, already running stores online and several successful brick-and -mortar shops, selling a range of experiential products that feature the creative use of cannabis. Established already in key markets like Toronto and Calgary, Tokyo Smoke’s cannabis will soon be on shelves in legal recreational dispensaries in the United States.

East meets West in merging of cannabis retail and production minds

Partnering with Doja Cannabis, a seasoned Kelowna-based pot producer, was Gertner’s first foray into production. The strategy of merging minds with industry expertise in producing and retailing pot brought Gertner, based in the east, and Kitsch, based in the west, to a new market in the Manitoban middle ground.

The cannabis industry is growing at a rapid pace. While powerful players are teaming up to establish brand presence and formulate creative ways to differentiate themselves, the smaller contenders will begin to get weeded out. With Manitoba’s major retail cannabis players now clear, the stage is set for companies to continue their push toward becoming Canada’s first dominant cannabis retailers. HIKU, with shares trading over $2.50 and an estimated market cap topping $300 million, is definitely one to watch.

Comparables:

Aphria (NASDAQ: APHQF) (TSE: APH) was founded in 2011 and is headquartered in Leamington, Ontario. The company calls itself one of the lowest-cost producers of marijuana, and produces dry cannabis, as well as cannabis oil of varying qualities and strength. Its cannabis is 100 percent greenhouse grown. Aphria’s estimated market cap is over $2 billion.

Canada’s largest producer, Canopy Growth (OTC: TWMJF) (TSE: WEED), has a market cap of more than $4 billion, with shares currently trading over $22, a 61.3% increase over the last three months. Formerly known as Tweed Marijuana Inc., Canopy Growth was founded by Bruce Linton in 2014, and is based in Smiths Falls, Ontario. Canopy Growth is the first federally regulated, publicly traded cannabis producer in North America. It operates numerous production facilities across Canada and around the world with over 700,000 square feet of production licensed under Canada’s medical cannabis framework.

National Access Cannabis (OTC: NACNF) (CSE: NAC) National Access Cannabis’ market cap is over $135 million; stock is trading over $1. The company operates medical cannabis care centers across Canada, National Access is adapting its established medical clinic model to meet the needs of the Manitoba retail market. National Access works alongside Health Canada and Licensed Producers to help qualifying patients gain access to their license. After receiving the Manitoba retail National Access announced it intends to deepen its relationships with CannaRoyalty Corp. and Cannabis Wheaton Income Corp.

MedReleaf (TSE: LEAF) (OTC: MEDFF) was voted Top Licensed Producer at the Lift Canadian Cannabis Awards. MedReleaf is an Ontario- based, R&D-driven company dedicated to innovation, and delivering products to the global medical market, and providing brands and product assortment for the recreational consumer market. MedReleaf’s market cap is currently over $2.26 billion.

For a more in-depth look into HIKU Brands, visit HIKU Brands (CSE:HIKU; OTCBB: DJACF) or read the FULL Report: Cannabis Investors Need Three M’s To Success: Money, Moxie, and Management

About CannabisNewsWire

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

Friday, February 23rd, 2018 Uncategorized Comments Off

$VSQTF Pursuing Opportunities to Leverage Blockchain, NetworkNewsAudio Audio Press Release

New York, New York–(Newsfile Corp. – February 23, 2018) – NetworkNewsAudio announces the Audio Press Release (APR) titled “Five Blockchain Companies to Watch in 2018,” featuring Victory Square Technologies, Inc. (CSE: VST) (OTC: VSQTF) (FWB: 6F6).

To hear the NetworkNewsAudio version, visit: http://nnw.fm/xH95v

To read the original editorial, visit: http://nnw.fm/ALGc8

In December 2017, Victory Square Technologies joined the Blockchain Investors Consortium (“BIC”), an influential group with more than $2 billion of digital assets. BIC pools member experience and expertise in shared due diligence efforts to identify investment opportunities in the most promising and disruptive blockchain-enabled companies.

The membership enabled a pathway for Victory Square Technologies to take an early-mover position in the Initial Coin Offering (“ICO”) rush via participation in Bluzelle’s (“BLZ”) early contributor round token sale (http://nnw.fm/8kxfC). With the purchase of a $250,000 allocation of BLZ tokens, Victory Square also received 25 percent more tokens for its contribution.

Victory Square also retained Bluzelle CEO Pavel Bains as a strategic advisor to help advance Victory Square’s Blockchain Assembly portfolio company, leveraging his expertise in blockchain and fintech, including ICOs and tokens.

About Victory Square Technologies Inc.

Victory Square is a venture builder that creates, funds and empowers entrepreneurs predominantly focused on blockchain technology, virtual reality, artificial intelligence, personalized health, gaming and film. As a technology incubator, Victory Square invests in game-changing entrepreneurs who are provided access to education programs, global mentorship networks, distribution partners, creative workspaces, resources and other forms of operational support to help them scale internationally. For more information, visit www.VictorySquare.com.

About NetworkNewsAudio

NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

For more information, visit: www.NetworkNewsAudio.com

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit https://www.NetworkNewsWire.com.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Friday, February 23rd, 2018 Uncategorized Comments Off

$ETST European Industrial Hemp and Mr. Checkout Could be Key Players in 2018

February 23, 2018

ETST projects a breakout year in 2018 from its new line of High Grade Full Spectrum Cannabinoids, marketed as a cannabinoid complex
Checkout sells to major retailers, such as Walmart and Target, as well as a network of independent distributors and retail owners
ETST’s new line is sourced from European industrial hemp, but it is mixed, bottled and packaged in the U.S.

Earth Science Tech, Inc. (OTC: ETST) is projecting a breakout year in 2018, resetting its executive team and implementing a new marketing strategy. Playing key roles in the predictions of higher volume and performance are new Netherlands-sourced industrial hemp-based products and Mr. Checkout, the specialty distributor that focuses on retail placement (http://nnw.fm/1NpT6).

The company recently launched its revamped and repackaged line of industrial hemp products as a cannabinoid complex. It uses a CO2 extraction process with organically grown and unfiltered industrial hemp. It sources the product from Europe, but it is mixed, bottled and packaged in the U.S. The European Industrial Hemp Association (EIHA) is working with the World Health Organization (WHO) for a product review, and its next meeting is set for May 2018 (http://nnw.fm/6AL1f).

ETST is an innovative biotech company based in Doral, Florida. Its new line consists of High Grade Full Spectrum Cannabinoids product. It is focused on the cannabinoid, nutraceutical and pharmaceutical fields, and it also conducts R&D for certain medical devices. The new cannabinoid complex line is unique, because it offers the user a specific disclosure of the milligrams (mg) of each cannabinoid. The cannabinoid complex is rich in Terpenes and Saponins, ETST said.

Mr. Checkout, a distributor originally launched in 1989, specializes in distribution to major retailers, such as Walmart, Target and Walgreens, and it also to a network of 1,100 independent distributors and 50,000 independent retail owners within a national network in the U.S. It also offers comprehensive logistics expertise in shipping and boasts a ‘Fast Track’ program designed to get product onto retail shelves quickly (http://nnw.fm/kbLY2).

ETST markets a 100 percent natural and organic high grade hemp cannabidiol and holds three wholly-owned subsidiaries: Earth Science Pharmaceutical has a line of low-cost, non-invasive medical devices for the detection of sexually transmitted diseases (STDs); Cannabis Therapeutics is an emerging biotechnology company; and KannaBidioilD is targeted to the recreational market.

For more information, visit the company’s website at www.EarthScienceTech.com

More from NetworkNewsWire

About NetworkNewsWire

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Friday, February 23rd, 2018 Uncategorized Comments Off

$PVOTF “Seed to Derivatives” – Vertical Integration in Burgeoning Cannabis Market

February 23, 2018

Letter of Intent to acquire Agro-Biotech, to become vertically integrated from “seed to derivatives”
Development and commercialization of therapeutic pharmaceuticals and nutraceuticals
Patented formulation and delivery technologies

Scientific studies have provided empirical credence to the medical efficacy of cannabinoids for multiple maladies. Globally, researchers and biopharmaceutical companies are now laser focused on cannabinoid-based therapeutics that may hold blockbuster medical potential, providing solutions to a range of unmet medical needs. However, current drug delivery techniques remain antiquated. There are inherent metabolic and bioavailability issues affecting the consistent, effective delivery of cannabinoids. It’s becoming clear that these new pharmaceutical therapeutics require revolutionary delivery techniques. Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) is establishing new paradigms in cannabinoid drug development and delivery.

Pivot Pharmaceuticals is transforming the development and commercialization of these new therapeutic pharmaceuticals and nutraceuticals with unique drug delivery platform technologies. Pivot’s medical cannabis product division, Pivot Green Stream Health Solutions (PGS), conducts research, development, and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals, and it has acquired worldwide rights to BiPhasix™ Transdermal Drug Delivery platform technology (topical) and Solmic Solubilisation technology (oral) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. The company recently filed three provisional patents for cannabinoid-based product delivery with the U.S. Patent and Trademark Office (http://cnw.fm/2e8HS), and these latest patent filings join an established number of global rights to topical, oral, transdermal, food and beverage technologies that Pivot has already secured.

Pivot’s pipeline of potential CBD-based pharmaceuticals now covers treatment indications for supportive care to relieve nausea, mucositis and pain, including cancer-related and menstrual pain, dermatological conditions and even glaucoma. Pivot is also developing and commercializing an array of pharmaceutical-grade formulations for cannabinoid-based consumer health care products.

With enhanced drug delivery and development well underway, Pivot has turned to its next business objective, vertical integration. The company just announced a Letter of Intent for the proposed acquisition of Agro-Biotech, a Québec-based ACMPR Canadian licensed cannabis producer (http://cnw.fm/rGD5M). Agro-Biotech operates a fully licensed, purpose-built, indoor hydroponic cannabis production facility capable of producing a cumulative 10,000 kilograms per year.

Pivot is already a differentiated player in the Canadian cannabis industry due to its unique approach to enhanced dosing and bioavailability of cannabinoids with proven pharmaceutical and patented formulation and delivery systems. With the acquisition of Agro-Biotech, Pivot Pharmaceuticals expects to become vertically integrated, controlling the entire manufacturing process from “seed to derivatives” and capturing margin along the entire supply chain.

In the news release, Dr. Patrick Frankham, Pivot CEO, stated, “I am delighted to welcome Agro-Biotech to Pivot… With this acquisition, we are well positioned to enter the Québec cannabis market and attract experienced scientists to our organization. Pivot will seek to expand its footprint in the province beginning immediately following financing activities which are underway. After several months of identifying and discussing with potential partners in the cannabis space, the Pivot management team and our scientific advisors agreed that it was in the best interest of our shareholders to acquire the compliment of licenses which will enable us to develop our pipeline of patented formulation and delivery technologies all under one vertically integrated process from seed to derivatives. Pivot will only work with partners who truly control their processes and have the finest infrastructure and qualified personnel. We believe that these characteristics will define best in class products for wellness and health conscious consumers using bio-cannabis….”

This latest announcement follows a pattern of strong corporate development by Pivot Pharmaceuticals and uniquely positons the company to become a major force in the burgeoning cannabis markets not only in Canada but around the world.

For more information, visit the company’s website at www.PivotPharma.com

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Friday, February 23rd, 2018 Uncategorized Comments Off

$NETE Joins the Enterprise Ethereum Alliance – NetworkNewsBreaks

Prestigious Enterprise Ethereum Alliance welcomes Net Element to its network of innovative companies

MIAMI, FL, Feb. 21, 2018 — Net Element, Inc. (NASDAQ: NETE) (“Net Element” or the “Company”), a global technology and value-added solutions group, today announces that it has joined the Enterprise Ethereum Alliance (“EEA”), the world’s largest open-source blockchain initiative with over 250 member companies. Net Element’s membership to the prestigious alliance is complementary to the Company’s recently announced decentralized blockchain technology solution that will enable an unlimited number of value-added services (“VAS”) and support the adoption of Ethereum in the enterprise.

The EEA seeks to augment Ethereum adoption as an enterprise-grade technology, with research and development focused on privacy, confidentiality, scalability and security. Net Element is developing a decentralized crypto-based ecosystem to act as a framework for a number of value-added services that can connect merchants and consumers directly, via blockchain technology, while increasing the economic efficiency of all transactions conducted within the ecosystem.

Part of this initiative is the Company’s recently launched Netevia platform which delivers end-to-end multi-channel payment processing through easy-to-use APIs, point-of-sale (“POS”), e-commerce and mobile devices. Netevia’s blockchain solution, code-named “VIA Protocol,” is currently under development and is intended to enable new billing methodologies over the blockchain as well as create dynamic service offerings such as rewards, loyalty and one-click payments.

“EEA’s rapid growth in membership mirrors the accelerating acceptance and deployment of Ethereum blockchain solutions in the global marketplace,” says Julio Faura, EEA’s chairman of the board. “The technological breadth, depth and variety of organizations coming together under the auspices of EEA to create and drive enterprise Ethereum standards bodes well for the future development of the next-generation Ethereum ecosystem.”

“We are excited to be a part of the Ethereum Alliance, which connects Fortune 500 enterprises, startups, academics and technology vendors with Ethereum subject matter experts,” comments Net Element CEO Oleg Firer. “We look forward to leveraging the EEA network as we build more value for our community by developing our blockchain ecosystem for value-added services.”

“Net Element is focused on delivering value-added solutions for our community as we develop decentralized blockchain solutions to connect merchants and consumers. Alongside leading global enterprises, such as Microsoft, Intel, JPMorgan, Samsung, ING, MasterCard, Thomson Reuters, Cisco Systems, and others, we have partnered with EEA to establish clear roadmap, robust governance model, and useful Ethereum resources.”

About The Enterprise Ethereum Alliance
The EEA is an industry-supported, not-for-profit established to build, promote, and broadly support Ethereum-based technology best practices, open standards, and open-source reference architectures. The EEA is helping to evolve Ethereum into an enterprise-grade technology, providing research and development in a range of areas, including privacy, confidentiality, scalability, and security. The EEA is also investigating hybrid architectures that span both permissioned and public Ethereum networks as well as industry-specific application layer working groups.

EEA will collectively develop open industry standards and facilitate collaboration with its member base and is open to any members of the Ethereum community who wish to participate. This open-source framework will enable the mass adoption at a depth and breadth otherwise unachievable in individual corporate silos and provide insight to the future of scalability, privacy, and confidentiality of the public Ethereum permissionless network. Further information is available at www.entethalliance.org.

About Net Element
Net Element, Inc. (NASDAQ: NETE) operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the U.S. and selected emerging markets. In the U.S. it aims to grow transactional revenue by innovating SME productivity services using blockchain technology solutions and Aptito, our cloud based, restaurant and retail point-of-sale solution. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500™. In 2017 we were recognized by South Florida Business Journal’s as one of 2016’s fastest growing technology companies. Further information is available at www.netelement.com.

Forward-Looking Statements
Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Net Element and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to the timing of completion of new features for the Netevia platform, whether contemplated projects and the utilization of blockchain technology will be successful, whether the addition of blockchain technology-focused payment processing solutions business will become a framework for multiple value-added services, whether the Company will be successful in expansion and growth endeavors; and even if it is successful in any or all of these endeavors, whether this will positively impact the Company or result in improved shareholder value. Additional examples of such risks and uncertainties are: (i) Net Element’s ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Net Element’s ability to maintain existing, and secure additional, contracts with users of its payment processing services; (iii) Net Element’s ability to successfully expand in existing markets and enter new markets; (iv) Net Element’s ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Net Element’s business; (viii) changes in government licensing and regulation that may adversely affect Net Element’s business; (ix) the risk that changes in consumer behavior could adversely affect Net Element’s business; (x) Net Element’s ability to protect its intellectual property; (xi) local, industry and general business and economic conditions; (xii) adverse effects of potentially deteriorating U.S.-Russia relations, including, without limitation, over a conflict related to Ukraine, including a risk of further U.S. government sanctions or other legal restrictions on U.S. businesses doing business in Russia. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K filed by Net Element with the Securities and Exchange Commission. Net Element anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Net Element assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Net Element, Inc.
1-786-923-0502
media@netelement.com

Thursday, February 22nd, 2018 Uncategorized Comments Off

$VSQTF to Enter Definitive Agreements to Acquire 28.5% of Howyl Ventures

VANCOUVER, British Columbia, Feb. 22, 2018 — Subject to all requisite regulatory approvals, Victory Square Technologies Inc. (“Victory Square” or the (“Company”) (CSE:VST)(OTC:VSQTF)(FWB:6F6) will acquire 28.5% of all issued and outstanding shares of Howyl Ventures Inc. (“Howyl”), and their decentralized project marketplace platform, Capaciti, for $1,000,000 CAD in total consideration (the “Purchase Price”).

Pursuant to definitive share purchase and subscription agreements to be executed between the Company and the shareholders of Howyl (the “Share Purchase Agreement”), and the Company and Howyl (the “Subscription Agreement”), respectively, the aggregate Purchase Price will be paid and satisfied by the Company through cash installments totalling $100,000 (the “Cash Consideration”) by the Company and the issuance of 364,372 common shares in the capital of the Company (the “Consideration Shares”) to the shareholder(s) of Howyl at a deemed issue price of $2.47 per Consideration Share. The deemed issue price represents the closing price of the common shares of the Company on the Canadian Securities Exchange at the end of trading on February 21, 2018, the trading day preceding this news release announcing this acquisition, less a discount of 10%. In accordance with the terms of the Share Purchase Agreement, the Consideration Shares shall be subject to resale restrictions, which permit 8% of the Consideration Shares to be eligible to be free-trading four months from the date of issuance to satisfy the statutory hold period and a further 8% every three months thereafter until the final balance of Consideration Shares is eligible to be free-trading in approximately three years’ time. The Share Purchase Agreement and Subscription Agreement also contain standard representations, warranties and covenants for transactions of this nature.

Capaciti will be the first enterprise-grade, decentralized project marketplace in the world. Its technology will fully complement the massive growth in digital freelancing, being driven by a convergence of connectivity, distributed skilled workers, a shift to output-oriented work, and the rise of “gig economy.”

“Our mandate at Victory Square is to invest in and partner with game-changing technology companies that are redefining the markets in which they operate,” said Victory Square’s CEO, Shafin Diamond Tejani. “Howyl’s existing global talent marketplace, combined with deep industry expertise and an exceptionally strong management and technical team, will bring Victory Square into another technology-driven vertical that will experience rapid growth over the next 10 years. The Howyl team has already demonstrated a successful track record of delivering projects using a distributed workforce model, with an alpha-version platform already being used internally to service existing client work.”

“Automation, digital platforms, and other innovations are changing the fundamental nature of work,” continued Shafin Diamond Tejani. “Howyl’s ‘Capaciti’ marketplace will allow for a frictionless work environment to enable the digital support of enterprise clients, and the pipeline of global talent that services those clients.”

The addressable market for Capaciti’s initial service offering is substantial. In the U.S. alone, the digital design market is estimated at $720bn/year, with 50% of that spend flowing to outsourced professionals (https://www.comptia.org/resources/it-industry-trends-analysis).

Howyl’s 2018 focus will be to continue building its proprietary talent marketplace, while continuing to grow both its base of customers and suppliers. Howyl’s projected revenue is already on-track to exceed $3,000,000 in 2018.

“The Victory Square team is a leader in helping technology companies rapidly scale and expand into global markets, and as a result, they are the ideal partner for Howyl to facilitate our next stage of growth,” states Marc Low, CEO of Howyl Ventures Inc. “Our vision of building a decentralized project marketplace for the enterprise, which addresses the changing nature of work, requires alignment with a strategic partner that can help us build and deploy our platform around the globe. Victory Square is the ideal partner for us in this respect.”

In consultation with Victory Square portfolio company Blockchain Assembly Inc., Howyl will look to raise additional funds for the development and implementation of its blockchain-enabled platform by performing a token generation event. Victory Square is excited to expand its enterprise offerings and looks forward to building upon early success stories like Blockchain Technology Limited (BTL.V), the first publicly-traded blockchain company in Canada.

For further information about the Company, please contact:

Investor Relations Contact – Prit Singh
Email: prit@victorysquare.com
Telephone: 905-510-7636

Media Contact – Howard Blank, Director
Email: howard@victorysquare.com

Telephone: 604-928-6066

ABOUT VICTORY SQUARE TECHNOLOGIES INC.
Victory Square Technologies is a blockchain-focused venture builder that funds and empowers entrepreneurs to implement innovative blockchain solutions. Victory Square portfolio companies are disrupting every sector of the global economy including Virtual Reality, Artificial Intelligence, Personalized Health, Gaming and Film. Victory Square has a proven process for identifying game-changing entrepreneurs and providing them with the partners, mentorship and support necessary to accelerate their growth and help them scale globally. For more information, please visit www.victorysquare.com.

ABOUT THE CANADIAN SECURITIES EXCHANGE (CSE)
The Canadian Securities Exchange, or CSE, is operated by CNSX Markets Inc. Recognized as a stock exchange in 2004, the CSE began operations in 2003 to provide a modern and efficient alternative for companies looking to access the Canadian public capital markets.

FORWARD-LOOKING INFORMATION
This news release contains “forward-looking information” within the meaning of applicable securities laws relating to the outlook of the business of Victory Square, including, without limitation, statements relating to the completion of the acquisition of an interest in Howyl and the timing, cost and terms thereof, the impact of the acquisition on the Company, the strategic direction of the Company, and its goal of broadening its portfolio of interests in innovative companies. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans”, “continues”, “project”, “potential”, “possible”, “contemplate”, “seek”, “goal”, or similar expressions, or may employ such future or conditional verbs as “may”, “might”, “will”, “could”, “should” or “would”, or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. All statements other than statements of historical fact contained in this news release are forward-looking statements. Forward-looking information is based on certain key expectations and assumptions made by the management of Victory Square. Although Victory Square believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on them because Victory Square can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements contained in this news release are made as of the date of this news release. Victory Square disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

Thursday, February 22nd, 2018 Uncategorized Comments Off

$PBIO Technology Could Provide Ideal Drug Delivery of Cannabinoids

February 15, 2018

The tide of cannabis legalization continues to rise
Medical cannabis market on pace to hit $56 billion in seven years
Company’s proprietary technology improves the bioavailability of cannabinoids

With the passage of laws permitting medicinal use of cannabis in at least 32 U.S. jurisdictions and Canada, producers of cannabinoids for medical purposes are racing to improve delivery methods for their formulations. Cannabinoids, such as cannabidiol (CBD), are hydrophobic (literally, afraid of water). In practice, this means they do not dissolve or emulsify readily in water, which may seem to pose a problem, since, by composition, the human body is more than half water. Yet, paradoxically, for a drug to be readily absorbed, it must be largely hydrophobic, yet not completely so. It must, to some extent, dissolve in water. As a result, new, patented technology from Pressure BioSciences Inc. (OTCQB: PBIO) may provide the ideal transport for CBD and other cannabinoids. PBIO’s Ultra Shear Technology (“UST”) has the capacity to develop water-soluble nanoemulsions that can be employed to improve the bioavailability of cannabinoids.

Emulsions are mixtures of two or more liquids (e.g., oils in water) that cannot be blended into each other without the addition of chemicals called emulsifiers (e.g., surfactants). Emulsions are used in multiple everyday products, including food, medical products, pharmaceuticals, nutraceuticals, cosmetics, industrial lubricants, and even cannabis oil extracts (e.g., CBD). Nanoemulsions have been shown to have improved absorption while providing higher bioavailability, greater stability and other advantages, when compared to the standard, much larger macro- and micro-emulsions.

Nanoemulsions offer an advanced mode of drug delivery that’s expected to improve the bioavailability of a wide range of active agents. These nano-sized emulsions, in which two immiscible liquids are usually combined to form a single phase by means of an emulsifying agent that combines surfactant and co-surfactant, typically have droplet sizes that fall in the 20–200 nanometer range. It would take 10 million nanometers to cover a length of one centimeter (about 0.4 inches).

Interestingly, PBIO believes that its patented UST may be able to make commercial-scale nanoemulsions that would require far less emulsifying agents than current methods, perhaps even none. Emulsifying agents are chemicals; some are natural, some are not. With consumer demands for non-additive natural products, the availability of nanoemulsions that require little or no chemical emulsifiers should be well received by consumers and manufactures alike, and rewarded by shareholders.

Late last year, PBIO announced a partnership with Phasex Corporation. The aim of the collaboration is to combine PBIO’s patented UST and Phasex’s supercritical fluid (“SCF”)-based processing methods to enable the development of stable, water-soluble nanoemulsions of nutraceuticals, including CBD-enriched plant oil. Phasex is a pioneer in the development of SCF-based toll processors, which are used for extracting, purifying, recrystallizing and fractionating a wide range of polymers, natural extracts and other chemicals.

Complementing Phasex’s SCF extraction technology with PBIO’s UST makes a great deal of commercial sense. Currently, there is a market for new methods of turning hydrophobic extracts into stable, water-soluble formulations. UST offers the potential to solve that problem by producing stable nanoemulsions of oil-like products in water. The range of commercial applications is extensive and includes inks, industrial lubricants, cosmetics, pharmaceuticals and nutraceuticals, as well as medically important plant oil extracts such as CBD. UST utilizes ultra-high pressure-driven fluid dynamic shear forces, combined with controlled temperatures, to engender homogenization.

Data from scientific studies indicate that nanoemulsions of nutraceuticals and pharmaceuticals may exhibit improved absorption, higher bioavailability, greater stability and lower levels of stabilizing additives (surfactants) when compared to the larger droplet sizes resulting from current emulsion processes. Because of these significant advantages, nanoemulsions are currently the focus of many research efforts worldwide. In this field, the PBIO-Phasex joint venture is poised to break new ground. Combining Phasex’s SCF extraction methodology with PBIO’s disruptive drug delivery technology may signal the genesis of an entirely new paradigm in therapeutic treatments.

The global medical marijuana market is set to reach a value of $55.8 billion by 2025, according to a new report by Grand View Research, Inc. As it expands, the demand for enabling medical technologies, such as UST, is set to rise. PBIO, it seems, is about to thrive in the brave new world of cannabis liberalization.

For more information, visit the company’s website at www.PressureBioSciences.com

More from NetworkNewsWire

About NetworkNewsWire

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Thursday, February 22nd, 2018 Uncategorized Comments Off

$CIIX Pursuing a Diversified Future in Cryptocurrency, Baijiu and Cannabis

February 22, 2018

Chinese investors seek cryptocurrency education as they adapt and continue to diversify portfolios with bitcoin
CBD Biotechnology advancing distribution of baijiu
CIIX planning to spin-off ChineseHempOil.com and CBD Biotechnology subsidiaries in order to focus on cryptocurrency markets

ChineseInvestors.com (OTCQB: CIIX) is an emerging leader in the adoption of cryptocurrencies and blockchain technologies. The company has been leading the way in providing financial information and education for Chinese-speaking investors in the United States and China since 1999. CEO Warren Wang believes that cryptocurrency and blockchain technologies will play a growing role in China’s future economy.

Currently, CIIX broadcasts a daily newscast titled ‘Bitcoin MultiMillionaire’ and operates www.NewCoins168.com, a free Chinese-language bitcoin education site. The company is ready to meet the challenges associated with a growing need for informed reporting and education among the rapidly emerging middle- and upper-class in China, as well as new investors. There are challenges on the horizon with the adoption of blockchain technologies (http://cnw.fm/U5Uci) that CIIX is ready to meet. Chinese investors have managed to adapt to the Beijing ban on cryptocurrency and continue to diversify their portfolios with bitcoin. CIIX is meeting the demand through innovative moves such as the recent addition of a bitcoin ATM in the lobby of its U.S. headquarters in California.

CIIX plans to focus on its new cryptocurrency division and core financial education business. Part of the process is to spin-off its CBD Biotechnology and ChineseHempOil.com subsidiaries, with plans to register them as a separate publicly traded company. This move will allow CIIX to focus more on educational services related to cryptocurrencies and blockchain technologies targeted at the Chinese public. It also offers new opportunities for its subsidiaries.

CBD Biotechnology Co. Ltd. acquired a wholesale alcohol License in China in 2017. The company has expanded its Chinese consumer division to include distribution of baijiu, a popular Chinese grain liquor, by aligning with China GuiZhou HanTai Wine, Inc. CBD Biotechnology has also partnered with Jinri Toutia (translation: Today’s Headlines) to strengthen its marketing platform. Both moves are in hope of strengthening CBD Biotechnology’s brand awareness and sustainable revenue growth.

CIIX’s goal, through subsidiary ChineseHempOil.com, is to become the leading publicly traded company targeting Chinese medicinal marijuana. The creation of an Apple App Store-approved Yelp-style app allows customers to find and recommend nearby locations for medical and recreational cannabis. The company has plans to open a retail store in San Gabriel, California, this year, and it continues to provide nutritional supplements containing CBD through its online platform at www.ChineseCBDoil.com.

For more information, visit the company’s website at www.ChineseInvestors.com

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Thursday, February 22nd, 2018 Uncategorized Comments Off

$ETST Advances in Prosperous Cannabis Industry – NetworkNewsBreaks

January 31, 2018

Cannabis industry expected to reach $24.5 billion in sales within four years
Company expanding into Canada ahead of expected nationwide legalization
Medical diagnostic device set for clinical tests to validate detection of STDs

With the sunny investment disposition toward marijuana and blockchain-related industries carrying over from late 2017’s marketplace into the new year (http://nnw.fm/3Kzml), Florida-based Earth Science Tech, Inc. (OTC: ETST) is optimistic about its ability to serve the medical and recreational needs of a growing population of cannabis users. The biotechnology company has established a research agreement with the University of Central Oklahoma and DV Biologics Laboratory to study and advance the health care benefits of its high-grade hemp CBD oil, placed its cannabidiol (CBD) food products in retail stores throughout the country, established a non-profit foundation to help underprivileged patients use its products and acquired Quebec, Canada-based Canna Inno Laboratories Inc. in a bid to expand into that country as it prepares to legalize the recreational use of marijuana on a national basis later this year.

Earth Science Tech, Inc. announced in May 2014 that it was entering the legal cannabis and medical marijuana industry as a natural progression of its mission to deliver wellness and alternative medicine options to American consumers. In the nearly four years since, a growing number of states have legalized medicinal and recreational uses for marijuana derivatives as popular sentiment has shifted toward acceptance of the drug despite its continued classification as a controlled substance by the federal government. The revolution in Canada that is expected to result in full legalization this summer has outpaced U.S. attitudes and provided a near-neighbor alternative for U.S. businesses that continue to encounter market obstacles at home.

Variances in forecasts about the market potential for the legal cannabis industry are measured in billions of dollars nowadays; cannabis industry analysts Arcview Market Research, in partnership with BDS Analytics, predicts that the market will reach $24.5 billion in sales within the next three to four years with a 28 percent CAGR that follows on a 33 percent increase between 2016 and 2017 despite ongoing federal prohibition (http://nnw.fm/pEAM5). As this market potential grows, Earth Science Tech is working to uplist under the OTCQB’s regulations for new Tier II Regulation A+ companies, with hopes for SEC approval by March.

The proposed uplisting will underpin efforts to raise an additional $4 million in operating capital so the company can complete planned projects advancing its brand in the United States and Canada. In December, Earth Science Tech announced a CBD product revamp and brand education strategy (http://nnw.fm/3nYfW) that it expected to launch by the end of January, along with a renewed push for major donors to help its non-profit foundation and a collaboration with a start-up accelerator in Canada to help it ramp up its brand awareness.

In February, the company plans to begin a nine-month series of human clinical trials on its new CBD formulation, which is designed to decrease cravings and the negative effects of withdrawal in addicts. If the trials prove successful, the product is set to launch in 2019 as a new addition to the stable of Earth Science Tech patent-pending offerings.

“We look to hit the ground running in 2018 with all we have lined-up in the first quarter,” president, director and COO Nickolas Tabraue stated in a news release. “We have other exciting discussions that are progressing well, and we will share those once any material developments have been finalized. Our story and vision will be seen very soon and we greatly appreciate all who have believed in us since the beginning.”

Another aspect of Earth Science Tech’s mission is to develop low-cost, noninvasive home-use diagnostic tools for sexually transmitted infections and/or diseases. The company’s first medical device has been labeled MSN-2, which is set for clinical tests under an agreement with Laboratories BNK Canada to ensure the device meets regulatory requirements as part of the company’s bid to meet the specific needs of women. Earth Science Tech has already established the MSN-2 device’s ability to detect chlamydia, and it now aims to validate similar results for gonorrhea, another sexually transmitted disease that can have permanent consequences for patients if untreated. The company also plans to add testing to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. The diagnostic testing market for STDs is expected to grow to $108 billion by 2019, according to Transparency Market Research.

For more information, visit the company’s website at www.EarthScienceTech.com

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Wednesday, February 21st, 2018 Uncategorized Comments Off

$PBIO Deal with ISS Shows Potential to Enhance Drug Discovery & Development

February 21, 2018

The two companies entered co-marketing and distribution agreement to be implemented worldwide
Pressure BioSciences’ high pressure generator technology can improve optical spectroscopy accuracy and data collection with potentially far-reaching impact on drug development
The joint technology will be promoted to scientists all over the world and is expected to generate increased sales starting this year

A leading developer and provider of innovative high pressure-based solutions to the global life sciences industry, Pressure BioSciences, Inc. (OTCQB: PBIO) has entered a two-year agreement with ISS, Inc., a prominent designer and manufacturer of advanced scientific instruments with more than 30 years of experience in the field. Under the agreement, the two companies will join their marketing and distribution efforts worldwide, as well as their own technologies to create an advanced high pressure optical spectroscopy system that’s expected to generate significant data that could be critical to the discovery and development of new biopharmaceutical diagnostics and drugs, according to a Pressure BioSciences press release issued on February 14, 2018 (http://cnw.fm/PdX88).

Optical spectroscopy is typically used by scientists all over the world as a powerful analytical method to generate and gather information about the composition of biological molecules. The collected data have multiple applications ranging from the design of new drugs to the development of preventive strategies against certain diseases. However, with high pressure optical spectroscopy, scientists have access to a more unique and effective way to study molecular interactions instantaneously and with a better control of reversibility and irreversibility, due to the easily adjustable duration and amount of applied pressure. This can greatly improve the speed and accuracy of data collection, helping scientists better understand how biological molecules function and interact, with a significant impact on the discovery and development of improved drugs and diagnostics.

ISS is confident that, by using Pressure BioSciences’ patented and game-changing pressure cycling technology (“PCT”) with its optical cell systems instead of current manual pressure generators, scientists will be able to “visualize biochemical reactions as they are happening in the pressure cell,” as noted by ISS President Dr. Ben Barbieri in a news release. “The Pressure BioSciences pressure generators will also facilitate automated and significantly faster data collection. Such systems could potentially have a significant and far-reaching impact on drug development and other important areas of biomedical research worldwide,” he added.

“This powerful combination of technologies will be promoted to scientists worldwide by both Pressure BioSciences and ISS, with the combined system expected to drive an increase in sales this year and beyond,” commented Dr. Nate Lawrence, PBIO VP of Marketing and Sales.

The ISS Agreement is the latest in a series of acquisitions and collaborations that Pressure BioSciences has entered into over the last few months, including, most notably, the acquisition of BaroFold, Inc.’s assets in December of last year and its entry into a strategic partnership with Phasex Corporation in October 2017. The BaroFold acquisition has significantly increased the company’s intellectual property estate by eight issued patents and several others that are pending, as noted by CEO Richard T. Schumacher on a ‘Stock Day’ podcast (http://cnw.fm/JBO5o).

With Phasex, the collaboration has allowed Pressure BioSciences to enter the fast-growing nanoemulsions market, where its proprietary PCT-based Ultra Shear Technology can be used with Phasex’s Supercritical Fluid processing to generate water-soluble, fully stable nanoemulsions. Ensuring stability of nanoemulsions has been a challenge until now, but this strategic collaboration has every chance to change that, leading to the further expansion of an already large market and an increase in the number of potential nanoemulsion applications in industries ranging from pharmaceuticals, nutraceuticals, cosmetics, paints and industrial lubricants to food and even medical cannabis (e.g., CBD).

Unlike most commercially-available emulsions, which tend to be unstable and sometimes inappropriate for human use due to a high amount of surfactants required, nanoemulsions have been shown to improve absorption, enhance stability, exhibit higher bioavailability, contain reduced amounts of surfactants and present multiple other advantages. Pressure BioSciences is confident that, with its patented Ultra Shear Technology, it will be able to develop commercial-scale nanoemulsions that require less emulsifying events, or even none at all.

For more information, visit the company’s website at www.PressureBioSciences.com

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Wednesday, February 21st, 2018 Uncategorized Comments Off

$NETE Joins the Enterprise $ETH Ethereum Alliance

Prestigious Enterprise Ethereum Alliance welcomes Net Element to its network of innovative companies

Net Element, Inc.
1-786-923-0502
media@netelement.com

Wednesday, February 21st, 2018 Uncategorized Comments Off

$VSQTF Among Five Blockchain Companies to Watch in 2018

February 21, 2018

NetworkNewsWire Editorial Coverage: Blockchain technology and cryptocurrency unarguably have the potential to alter the future of money, finance, transportation and national security. While an increasing number of blockchain plays wind their way through the investment community, Victory Square Technologies Inc. (CSE: VST) (OTC: VSQTF) (FRANKFURT: 6F6) (WKN: A2AKL8) (VSQTF Profile) is demonstrating a particular measure of blockchain innovation potential in a wide range of industries, including payment processing, mobile gaming, and more. Other companies seizing territory in the blockchain technology space include tech-giant IBM (NYSE: IBM), Walmart (NYSE: WMT), Visa (NYSE: V) and Hive BlockChain Technologies (TSX:HIVE.V) (OTC: HVBTF).

Why Victory Square Technologies is One to Watch

Experienced in backing new ventures, Victory Square Technologies Inc. (CSE: VST) (OTC: VSQTF) (FRANKFURT: 6F6) (WKN: A2AKL8) finances and engages entrepreneurs, bringing them into a fold of education programs, global mentor networks, and effective distribution partnerships.

The company has corporate history in entertainment, sports, finance, energy infrastructure, healthcare and gaming, and thus can intelligently ease pathways for blockchain technologies and companies into those sectors and others.

Victory Square’s impending CAD $1.9 million investment in emerging merchant processor PayVida Solutions Inc. is just one of the company’s anchors in the blockchain space (http://nnw.fm/jVxk5).

While the acquisition of a stake in PayVida enables Victory Square to invest in payment processing, the company’s most recent investment enables a unique position in one of the highest grossing segments of the entertainment industry.

Recognizing the opportunity to leverage blockchain with in the burgeoning global gaming market, Victory Square in mid-February disclosed an agreement to acquire 100 percent of Vancouver-based V2 Games Inc. for $2 million CAD (US$1.6 million) (http://nnw.fm/mD40h).

Founded as a game development and publishing studio, V2 Games now boasts an operating history of licensing large IPs, and was the first Canadian company to license the PAC-MAN IP for a mobile game. The company’s licensing portfolio also includes Hello Kitty, the NFL and the NBA. Leveraging its success in mobile gaming, V2 Games invests its returns into other gaming companies, providing them with seed capital and expertise needed to growth their business. Recent investments include Flow, an equity crowdfunding platform for blockchain-powered games; and AR blockchain company, Shape Immersive.

The virtual nature of modern gaming is pushing the global gaming industry into overdrive. Analysts forecast that the industry will reach nearly $109 billion by 2017 (http://nnw.fm/DW28q), with the mobile gaming segment gobbling up 42 percent of the market.

The integration of blockchain-based cryptocurrencies into this burgeoning industry will likely push gaming to unprecedented heights by providing gamers with even more options, rewards and upgrades.

V2 Games’ strategy is to leverage this growth, along with Victory’s Square’s expertise in blockchain and the public markets, to offer top-tier opportunities to retail investors while facilitating new financing opportunities in the gaming industry.

Establishing Industry Roots

For Victory Square, exponential success in blockchain means embedding in and pursuing opportunities in the broader ecosystem.

In December 2017, Victory Square Technologies joined the Blockchain Investors Consortium (“BIC”), an influential group with more than $2 billion of digital assets. BIC pools member experience and expertise in shared due diligence efforts to identify investment opportunities in the most promising and disruptive blockchain-enabled companies.

The membership enabled a pathway for Victory Square Technologies to take an early-mover position in the Initial Coin Offering (“ICO”) rush via participation in Bluzelle’s (“BLZ”) early contributor round token sale (http://nnw.fm/8kxfC). With the purchase of a $250,000 allocation of BLZ tokens, Victory Square also received 25 percent more tokens for its contribution.

Victory Square also retained Bluzelle CEO Pavel Bains as a strategic advisor to help advance Victory Square’s Blockchain Assembly portfolio company, leveraging his expertise in blockchain and fintech, including ICOs and tokens.

History of Blockchain Investments

As an early investor in blockchain technologies, Victory Square has a deep background and insights to share with affiliated companies. More than three years ago, Victory Square incubated and invested in BTL Group Ltd. (TSX:BTL), the first publicly traded blockchain company (http://nnw.fm/aUcJ3) with a current market cap of over US$220 million. It has also enabled the integration of blockchain technology into the betting website FansUnite, creating a blockchain FAN token to place wagers and building a more-easily verifiable and transparent betting platform.

At FansUnite, the success of blockchain’s technology is such that Darius Eghdami, co-founder and CEO of FansUnite, said, “We are confident it will become the gold standard among sports betting sites around the world.”

Aside from sports betting, Victory Square has diversified its portfolio into VR/AR gaming, personalized health and film.

Victory Square’s track record of strategic investments not only expands its portfolio of disruptive technology investments, but builds its momentum and pace in the broader blockchain industry.

Other Notable Companies in the Blockchain Space

IBM (NYSE: IBM) has already taken a big lead in blockchain tech for supply chain management, aiming to reduce cash cycle time, increase transaction visibility, and reduce the overhead and number of cost intermediates (http://nnw.fm/ct4LZ). Customs declarations are seen as a growth market for the technology (http://nnw.fm/5cxPP), due in large part to blockchain’s ability to ensure asset transfer integrity across a company’s entire supply chain via distributed ledger authentication, a network-driven capacity hailed as the answer to the difficult, costly, time-consuming and risk-inviting practice of maintaining such records via antiquated, sole-source in-house methods.

Walmart (NYSE:WMT), in collaboration with IBM, Chinese retailer JD.com (NASDAQ:JD) and Tsinghua University National Engineering Laboratory, recently reported the creation of a Blockchain Food Safety Alliance to improve food tracking and safety in China (http://nnw.fm/5Ip1c). In a test program, Walmart showed that the application of blockchain technology reduced the time it took to trace a grocery store’s mango supply chain back to its farm origins to two seconds from what had taken several days. While mangoes are rarely if ever lethal, each year one in 10 people fall ill globally as a result of food-borne diseases; of those, about 420,000 die. The blockchain-enabled ability to rapidly trace bad food to the source and eliminate it from the food chain will mark an important advance in food safety.

Visa (NYSE:V) began testing a new cross-border payments solution dubbed B2B Connect in late January, tying in with financial institutions such as UnionBank, The Bank of Tokyo-Mitsubishi UFJ (NYSE:MTU), and Korea-based Shinhan Financial Group. Visa said B2B Connect eliminates friction for cross-border transactions by using distributed ledger (blockchain) technology to enhance the speed, security and reliability of transactions. Other companies involved in the Visa BTB payment effort include blockchain firm Blocko, the Japan Bank Consortium and Woori Bank.

Hive BlockChain Technologies (HIVE.V, HVBTF), which listed on the Toronto Stock Exchange last September, plans to build bridges from the blockchain sector to traditional capital markets. HIVE has partnered with Genesis Mining Ltd., touted as the world’s largest cloud-based blockchain and cryptocurrency mining company, to build the next generation of blockchain infrastructure. HIVE owns state-of-the-art GPU-based digital currency mining facilities in Iceland that produce newly minted virgin digital currency like Ethereum around the clock, and is in the midst of a major expansion of operations into Sweden.

The Next Act

The rapid emergence of blockchain technology and its acceptance in multiple marketplaces present a possibility of a once-in-a-generation investment opportunities in a transformational technology, somewhat akin to the early dot-com days. The words “creative destruction” or “disruptive technology” hardly do credit to the beneficial upheavals pending in finance, payment processing, transportation and other industries as blockchain platforms become pervasive.

Especially well-positioned will be those tested investor-practitioners, such as Victory Square Technologies, who have the added perspective of industry experience outside of software to anticipate in which sectors blockchain platforms will be especially accepted, useful or profitable.

One thing is certain, there will be plenty of room for winners in the blockchain space. The market for blockchain-related products and services is expected to reach $7.7 billion in 2022, up from $242 million in 2017, an astonishing 32-fold increase, reports researcher Markets & Markets.

That huge increase in blockchain-related enterprise is expected in the next five years. But, as with the Internet, the real growth and shape of blockchain applications will likely be decades in the making.

For more information on Victory Square Technologies Inc. please visit: Victory Square Technologies Inc. (CSE: VST) (OTC: VSQTF) or please read: Blockchain Revolution Triggers Massive Profit Opportunity

About NetworkNewsWire

For more information, please visit https://www.NetworkNewsWire.com

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

Wednesday, February 21st, 2018 Uncategorized Comments Off

$CIIX Diversifies Methods of Reaching Global Chinese-speaking Audience

February 12, 2018

CIIX diversifies methods of reaching its global Chinese-speaking audience, with projects ranging from a daily video broadcast from the NYSE on cryptocurrencies to the development of a new social media mobile app for the cannabis industry
Company’s new mobile app expected to be the first Chinese-language app offering reviews and discussion of cannabis products
‘Bitcoin MultiMillionaire’ is the company’s daily video broadcast from the NYSE prepared for its unique and expansive audience

ChineseInvestors.com, Inc. (OTCQB: CIIX) is reaching out to the global Chinese-speaking community through both daily video broadcasts on cryptocurrencies and, soon, a new mobile app focused on reviews and discussion of cannabis products. CIIX is involved in both product areas. The company is a diverse educational and consulting firm targeting the Chinese-speaking community in both China and the U.S.

In cryptocurrencies such as bitcoin, the company is active in educational activities, produces a daily video broadcast from the NYSE titled ‘Bitcoin MultiMillionaire’ and hosts a Bitcoin ATM in the lobby of its San Gabriel, California, headquarters.

In cannabis, CIIX has ChineseHempOil.com, Inc., a wholly-owned subsidiary. That company markets, both online and through traditional retail, a line of hemp-based health products. The line consists of premium private label oil made from non-industrial hemp, manufactured using a CO2 extraction process.

The company’s new cannabis mobile app, focused on marijuana reaching social media, was noted in the January editions of both the Tiny Gems Newsletter (http://cnw.fm/hDX1G) and the Serious Traders Newsletter (http://cnw.fm/4qtlF).

While the company reaches out to its audience in new ways, its subsidiary, CBD Biotechnology Co., Ltd., is also expanding its line of luxury skincare products (http://cnw.fm/Eauh2). Its products have been approved for sale in China by the China Food and Drug Administration (CFDA). CIIX has scheduled the launch of four new hemp-infused products and a breakthrough magnetic mask. Additionally, as part of its strategic plan to boost revenues, it has aligned with China GuiZhou HanTai Wine, Inc. (http://cnw.fm/5krVp) to begin baijiu liquor sales. Baijiu is a grain-based Chinese alcoholic beverage.

For more information, visit the company’s website at www.ChineseInvestors.com

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Wednesday, February 21st, 2018 Uncategorized Comments Off

$STLHF Rapid Extraction Process Reinventing Lithium Industry

The lithium industry needs to modernize and upgrade its extraction processes if it is going to keep up with escalating market demand for battery grade lithium. And as Bloomberg reports, the world needs a lot of lithium – fast.

The industry needs a modernizing evolution because extraction methods border on archaic – the process was designed around the 1960’s, and it hasn’t been advanced because the demand for battery-grade lithium materials has only really taken off in the last few years.

Currently Albemarle (NYSE: ALB) is the only company producing lithium inside the United States – in Nevada’s Clayton Valley. Companies like Chilean multinational Sociedad Química y Minera (NYSE: SQM), Nemaska Lithium (NMX. TO) and Lithium Americas (NYSE: LAC) are scrambling to speed up processes.

A main reason for Tesla’s (NASDAQ: TSLA) existence is that Lithium ion batteries have a high-enough charge capacity to make Battery Electric Vehicles viable.

Headquartered in Vancouver, the junior mining company capital of the world, Standard Lithium (TSX.V:SLL) (OTC:STLHF) is building an impressive portfolio of brownfield U.S. based lithium brine assets, fast-tracking a path to production and linking lithium carbonate to global markets from its project sites deep in the investor heartland of the United States.

CEO Robert Mintak and President Dr. Andrew Robinson partnered to launch Standard Lithium last year. The pair formerly founded and operated Pure Energy Minerals, recognized as the top mining company in the 2016 TSX Venture 50.

“Batteries are now 40 per cent of the use of lithium worldwide – and it’s going to be approaching 60% by 2020,” Mintak said. “The industry is now looking for an evolution. It’s at a tipping point where brine producers need to step up their game if they’re going to compete with hard rock producers to bring projects online quickly.”

“The industry has been operating, basically, with mid-20th century technology for the past 50 plus years. Over half of the lithium can be lost when it is being extracted from the ground because the process is so rudimentary. A lot of companies are chasing after modern processing.”

In January, Standard entered into an agreement with Canaccord Genuity, as sole bookrunner and lead underwriter on behalf of a syndicate of underwriters. The Underwriters agreed to purchase 9,530,000 units of the Company for $20 million. Standard also signed an agreement with TETRA Technologies (NYSE: TTI) for up to 33,000 acres of brine leases in a key production fairway in Southern Arkansas.

Standard has two Lithium brine projects: Bristol Dry Lake in California’s Mojave Desert, and the Smackover Project in Southern Arkansas. At both sites, but especially in Arkansas, the company is set to revolutionize the Lithium Industry by applying modern processing methodologies with the goal of fast-tracking production – bringing the lithium recovery from brine process time down from as long as two years to an astonishing 72 hours.

The location of the Smackover projet is ideal, the agreements that Standard has signed allows them immediate access to brine, and the Arkansas project sits in close proximity to key infrastructure already in place. The site is close to the ports of the Gulf of Mexico.

Until now, no one has built a new lithium project using modern extraction methods.

Standard Lithium is demonstrating faster production through its immediate access to thousands of litres of brine with good lithium concentration. This modernized, 72-hour selected extraction process is a game changer, Mintak said.

“In the same way that shale, or unconventional oil, affected the oil and gas industry, a modern, selective extraction process will reinvent the way people look at lithium projects,” he said.

Mintak says the best place in the world to demonstrate that is Arkansas. “We have everything we need; we have brine that is rich in lithium — it can be produced in amazing volumes.”

“The demand for lithium is real. The world is going to need a lot more lithium, and there are a lot of companies chasing after it, but you need to be able to show a path to production – and a fast-track to production,” Mintak said. “There are a lot of companies chasing after modernizing the Lithium extraction process. The smart ones are looking to go in as few steps from raw brine to a battery-grade lithium material.”

“Generally exploration companies chase after grade all they want – but lithium projects these are chemical processes facilities, you need manpower, infrastructure, re-agents and water to name a few if aim to produce high-quality, high- margin materails that the end user is going to require,” Mintak said.

Standard is pioneering a range of new technologies, and in addition to aligning with existing permitted operators like Tetra, Standard is working with a range of technology partners to apply the right process technology appropriate to the project.

“We knew the only significant, large-scale opportunity in North America where we could execute our business model was in Arkansas. “We recognized that we couldn’t secure a large land position by ourselves because the mineral claims reside on private property, so we built a great relationship with an operator there, and that relationship has allowed us to turn Arkansas into arguably the biggest opportunity in the Lithium space right now.”

“It is the best showcase in the world for a modern lithium process to be staged.”

Infrastructure exists on the Smackover site that doesn’t exist on other Lithium sites in remote locations, such as high-altitude sites in South America. At the Arkansas site, producers have been extracting for decades, with billions and billions of barrels of brine successfully pulled out and put back into the basin.

“The infrastructure is amazing, we have a highly trained workforce of brine handlers, and we’ve put together a really strong team of technical engineers who are very familiar with the chemistry process required – extraction experts,” Mintak said. “We’ve aligned ourselves with the current operators in Southern Arkansas to manage to secure the only large land lease available.”

Mintak believes that this is the only available chunk of brine leases that producers can access now. It could take years for competitors to try to piece together a land package.

Standard also signed an agreement to build a pilot plant adjacent to one of the existing brine processing chemical facilities in Southern Arkansas, where they will be able to tie into an existing pipeline, gain access to the existing brine supply, and work inside a permitted facility. And for the initial demonstration pilot plant stage, brine will also be shipped from Standard’s California site to Arkansas by rail car enabling the company to run both projects through the same test facility.

“We’ve got the perfect alignment, with the agreements and projects that we have secured, to demonstrate and build a US lithium asset utilizing a modern process,” Mintak said. “While other companies are chasing around, saying they are working on around trying to do it, we have access to all the elements required. It’s already underway, we are working on this everyday. And we’re going to build upon it.”

COMPARABLES:

Albemarle (NYSE: ALB)

Albemarle Corporation globally develops, manufactures, and markets engineered specialty chemicals, with project sites across the United States, and in South America, the Middle East, Africa and Asia. The company is currently producing lithium from brines in Nevada, producing over 6,000 tonnes of lithium carbonate per year from its Silver Peak operations. Albermarle announced that it has developed a technology that can increase production up to 125,000 tons of lithium carbonate equivalent without additional brine pumping and is expected to increase production to 80,000 tons a year by 2020.

Nemaska Lithium Inc. (TSX: NMX) (OTCQX: NMKEF)

Nemaska engages in the exploration and evaluation of lithium hard rock mining properties in Canada. Its Whabouchi property consists of 33 claims covering an area of 1,716 hectares located in the Eeyou Istchee/James Bay area of Quebec; and its Sirmac property, comprises 24 mining claims covering an area of 1,101 hectares located to the north-west of Chibougamau.

Lithium Americas (TSX: LAC) (NYSE: LAC)

Lithium Americas, together with Sociedad Quimica y Minera de Chile S.A. (“SQM”), is developing the Cauchari-Olaroz lithium project, located in the Province of Jujuy, Argentina, through its 50% interest in Minera Exar S.A. In addition, Lithium Americas owns 100% of the Lithium Nevada project (formerly Kings Valley project), and RheoMinerals Inc., a supplier of rheology modifiers for oil-based drilling fluids, coatings, and specialty chemicals.

Tesla Inc. (NASDAQ: TSLA)

Tesla, Inc. (formerly Tesla Motors) specializes in electric automotives, energy storage and solar panel manufacturing. Founded in 2003 by Elon Musk, the company specializes in electric cars, lithium-ion battery energy storage, and residential photovoltaic panels.Tesla also sells the Tesla Powerwall ad Powerpack batteries, solar panels and solar roof tiles. Tesla’s Model S was the world’s best-selling plug-in electric car in 2015 and 2016.

Wednesday, February 21st, 2018 Uncategorized Comments Off

$ONTX Two Presentations at 2018 American Chemical Society

Product stability studies for rigosertib, a Phase 3 clinical stage product in development for Myelodysplastic Syndromes (MDS)
Discovery of a novel kinase inhibitor, ON 150030, a Type 1 inhibitor of FLT3 and Src for relapsed and refractory Acute Myeloid Leukemia (AML)

NEWTOWN, Pa., Feb. 20, 2018 — Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that the Company’s scientists, and collaborators from the Mount Sinai School of Medicine, will present two abstracts at the American Chemical Society National Meeting & Expo. The meeting is being held in New Orleans, LA, on March 18-22, 2018.

The first abstract relates to the analysis of stability of the clinical product during storage and describes the synthesis and characterization of a de-sulfonylated product of rigosertib, Onconova’s lead phase 3 stage clinical candidate. The second abstract describes a new chemical entity ON 150030, which is a type 1 novel pre-clinical stage inhibitor of FLT3 and Src pathways, believed to be important for targeted therapy of relapsed and refractory AML.

Details for the poster presentations are listed below.

Title: Synthesis and characterization of de-sulfonylated product of rigosertib, a late phase III clinical candidate

Date: 18^th March, 2018

Presentation Time: 7.00-9.00 PM CDT

Presenter: Dr. M.V. Ramana Reddy & Dr. Muralidhar Mallireddigari

Location: Ernest N. Morial Convention Center, Hall E.

Title: Discovery of a novel kinase inhibitor ON 150030, a type 1 inhibitor for relapsed and refractory AML

Date: 18^th March, 2018

Presentation Time: 7.00-9.00 PM CDT

Presenter: Dr. M.V. Ramana Reddy

Location: Ernest N. Morial Convention Center, Hall E.

About Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS). Rigosertib, Onconova’s lead candidate, is a proprietary Phase 3 small molecule agent, which we believe blocks cellular signaling by targeting RAS effector pathways. Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells. Onconova has three product candidates in the clinical stage and several pre-clinical programs. Advanced clinical trials with the Company’s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS. For more information, please visit http://www.onconova.com.

About IV Rigosertib

The intravenous form of rigosertib has been employed in Phase 1, 2, and 3 clinical trials involving more than 800 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with higher-risk MDS, after failure of hypomethylating agent, or HMA, therapy.

About INSPIRE

The INternational Study of Phase III IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency and derives from the findings of the ONTIME Phase 3 trial. INSPIRE is a multi-center, randomized controlled study to assess the efficacy and safety of IV rigosertib in HR-MDS patients who had progressed on, failed to respond to, or relapsed after previous treatment with an HMA within the first 9 months or nine cycles over the course of one year after initiation of HMA treatment. This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Following interim analysis in early 2018, the independent Data Monitoring Committee recommended that the trial continue with an expansion in enrollment to 360 patients based on a pre-planned sample size re-estimation. Patients are randomized at a 2:1 ratio into two treatment arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care. The primary endpoint of INSPIRE is overall survival. Full details of the INSPIRE trial, such as inclusion and exclusion criteria, as well as secondary endpoints, can be found on clinicaltrials.gov (NCT02562443).

About Oral Rigosertib

The oral form of rigosertib was developed to provide more convenient dosing for use where the duration of treatment may extend to multiple years. This dosage form may also support many combination therapy modalities. To date, 368 patients have been treated with the oral formulation of rigosertib. Initial studies with single-agent oral rigosertib were conducted in hematological malignancies, lower-risk MDS, and solid tumors. Combination therapy of oral rigosertib with azacitidine and chemoradiotherapy has also been explored. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy. A Phase 1/2 trial of the combination therapy has been fully enrolled and the preliminary results were presented in 2016. This novel combination is the subject of an issued US patent with earliest expiration in 2028.

Forward Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova Therapeutics, Inc.’s expectations regarding the INSPIRE Trial. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Onconova has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including Onconova’s ability to continue as a going concern, the need for additional financing and current plans and future needs to scale back operations if adequate financing is not obtained, the success and timing of Onconova’s clinical trials and regulatory approval of protocols, and those discussed under the heading “Risk Factors” in Onconova’s most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q.

Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

General Contact

http://www.onconova.com/contact/

Investor Relations Contact

Katja Buhrer, Affinity Growth Advisors on behalf of Onconova Therapeutics

Katja.Buhrer@affinitygrowth.com / (212) 661-7004

Tuesday, February 20th, 2018 Uncategorized Comments Off

$CVRS Receives FDA Clearance for CorPath in PVI

Expanded Indication Extends Robotic Precision to Broader Patient Base with Vascular Disease

Corindus Vascular Robotics, Inc. (NYSE American:CVRS), a leading developer of precision vascular robotics, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for use of its CorPath GRX System in peripheral vascular interventions. The CorPath System is the first and only FDA-cleared medical device to bring robotic precision to both percutaneous coronary intervention (PCI) and peripheral vascular intervention (PVI) procedures.

The advanced CorPath GRX System broadens the capabilities of the CorPath robotic technology platform from exclusively treating coronary artery disease (CAD) to include peripheral artery disease (PAD). It is estimated that 8.5 million people in the United States are living with PAD, a disease of blood vessels outside the heart that commonly affects arteries carrying blood to the lower extremities. In 2017, peripheral procedures were estimated to be a $3.4 billion market, and it is estimated that by 2020, one million PAD procedures will be performed annually in the U.S.^1,2

“My colleagues and I have seen first-hand how CorPath GRX can overcome the challenges of manual PCI and I am excited to apply the capabilities of robotics to effectively treat PAD patients,” said Alan Lumsden, M.D., Chief of the Department of Cardiovascular Surgery at Houston Methodist Hospital. “As a training site for future robotic interventionalists, I look forward to teaching these techniques to further enhance the quality of care for patients with both CAD and PAD.”

“CorPath GRX enables me to provide transformational treatment options to my patients suffering from PAD,” said Joseph Ricotta, M.D., Medical Director of Vascular Surgery and Endovascular Therapy, Tenet Healthcare, Professor of Surgery, Charles E Schmidt College of Medicine, FAU. “As a long-time adopter of robotics, I am passionate about the opportunity this technology presents to advance endovascular care while providing a safer work environment for healthcare providers.”

Mark Toland, President and Chief Executive Officer of Corindus, stated, “The ability to treat patients with PAD using CorPath GRX is a significant step for Corindus as we expand the usage of our technology beyond PCI. The new indication aligns with our objective to provide more patients access to the benefits of precise robotic treatment while protecting healthcare professionals from harmful radiation during lengthy PVI procedures. We will continue to improve upon our technology platform with a keen focus on providing physicians the tools necessary to enhance patient care across the spectrum of interventional medicine.”

About Corindus Vascular Robotics

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company’s CorPath^® System is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and percutaneous vascular procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. CorPath GRX is the second generation robotic-assisted PCI technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit “One Stent Program.” For additional information, visit www.corindus.com, and follow @CorindusInc.

Forward-Looking Statements

Statements made in this release that are not statements of historical or current facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus’ control.

Examples of such statements include statements relating to Corindus’ ability to successfully expand the usage of the CorPath GRX System for peripheral artery disease (PAD) and the anticipated size of the PAD market.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, including, but not limited to the following: the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date. More information is available on Corindus’ website at http://www.corindus.com.

______________________

¹ Millennium Research Group 2013 Peripheral Vascular Devices US 2013 Market Analysis RPUS 11PV14 p 98.

² cdc.gov/PAD.

Corindus Vascular Robotics, Inc.
Media Contacts:
Kate Stanton, 508-653-3335 Ext. 200
kate.stanton@corindus.com
or
Investor Contact:
Lynn Pieper Lewis, 415-937-5402
ir@corindus.com

Tuesday, February 20th, 2018 Uncategorized Comments Off

$VYGR & $ABBV Announce Global Strategic Alzheimer’s Collaboration

Collaboration to include development of gene therapies consisting of vectors to deliver monoclonal antibodies to the brain directed against tau Voyager to receive $69 million upfront payment and potentially up to $155 million in preclinical and Phase 1 option payments as well as development and regulatory milestone payments and royalties

NORTH CHICAGO, Ill. and CAMBRIDGE, Mass., Feb. 20, 2018 — AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company, today announced that they have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer’s disease and other neurodegenerative diseases. This collaboration combines AbbVie’s monoclonal antibody expertise, global clinical development and commercial capabilities with Voyager’s gene therapy platform and expertise that enables generating adeno-associated viral (AAV) vectors for the treatment of neurodegenerative diseases.

In healthy individuals, tau is an abundant protein in the brain that promotes cellular stability and function. In the diseased brain, altered tau accumulates, resulting in impaired brain function and neuronal cell loss. The progressive spread of abnormal tau in the brain closely correlates with progressive neurodegeneration and symptom severity. However, one of the current limitations with the use of weekly or biweekly infusions of biologic therapies for neurodegenerative diseases is that only a small amount of drug is able to make its way into the brain. This collaboration seeks to develop a potential one-time treatment using Voyager’s gene therapy platform to reduce tau pathology through the delivery of an AAV vector antibody that encodes the genetic instructions to produce anti-tau antibodies within the brain.

“AbbVie is focused on developing treatments to meet the crushing public health crisis presented by Alzheimer’s and other neurodegenerative diseases,” said Jim Sullivan, Ph.D., vice president, pharmaceutical discovery, AbbVie. “Voyager’s vectorized antibody platform presents an innovative approach to addressing challenges in treating neurological disorders associated with the administration of biologic therapies. This collaboration has the potential to address the needs of patients who live with conditions such as Alzheimer’s disease, progressive supranuclear palsy and frontotemporal dementia.”

“Combining AbbVie’s leadership and deep expertise in monoclonal antibody discovery, development and commercialization and our ability to vectorize monoclonal antibodies is a natural fit, and we are very pleased to collaborate with AbbVie to advance this strategy towards the clinic in an effort to bring innovative treatments to patients,” said Steven Paul, M.D., president and chief executive officer of Voyager. “This collaboration also represents an important advance in our strategy to leverage our AAV gene therapy platform and programs through partnerships with biopharmaceutical companies that bring complementary expertise and capabilities, in addition to capital.”

Details of the collaboration and financial terms

Under the terms of the collaboration and option agreement, Voyager will perform research and preclinical development of vectorized antibodies directed against tau, after which AbbVie may select one or more vectorized antibodies to proceed into IND-enabling studies and clinical development. Voyager will be responsible for the research, IND-enabling and Phase 1 studies activities and costs. Following completion of Phase 1 clinical development, AbbVie has an option to license the vectorized tau antibody program and would then lead further clinical development and global commercialization for tauopathies, including Alzheimer’s disease and other neurodegenerative diseases. Voyager has an option to share in the costs of clinical development for higher royalty rates.

Voyager will receive an upfront cash payment of $69 million as well as up to $155 million in potential preclinical and Phase 1 option payments. In addition, Voyager is eligible to receive up to $895 million in development and regulatory milestones for each vectorized tau antibody compound and is eligible to receive tiered royalties on the global commercial net sales of the vectorized antibodies for tauopathies, including Alzheimer’s disease and other neurodegenerative diseases.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.

About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The company’s pipeline focuses on severe neurological diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of ALS, Huntington’s disease, Friedreich’s ataxia, frontotemporal dementia, Alzheimer’s disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, with AbbVie, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com.

Forward-Looking Statements: AbbVie

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” of AbbVie’s 2017 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Forward-Looking Statements: Voyager

This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “undoubtedly,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward-looking statements. For example, all statements Voyager makes regarding the potential benefits and future operation of the option and collaboration agreement with AbbVie, including any potential future payments thereunder, the initiation, timing, progress and reporting of results of its preclinical programs and clinical trials and its research and development programs, its ability to advance its AAV-based gene therapies into, and successfully initiate, enroll and complete, clinical trials, the potential clinical utility of its product candidates, its ability to continue to develop its product engine, its ability to develop manufacturing capability for its products, its ability to add new programs to its pipeline, its ability to enter into new partnerships or collaborations, its expected cash, cash equivalents and marketable debt securities at the end of a fiscal period and anticipation for how long expected cash, cash equivalents and marketable debt securities will last, and the timing or likelihood of its regulatory filings and approvals, are forward looking. All forward-looking statements are based on estimates and assumptions by Voyager’s management that, although Voyager believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. Such risks and uncertainties include, among others, those related to the initiation and conduct of preclinical studies and clinical trials, the availability of data from clinical trials and the expectations for regulatory submissions and approvals; the continued development of the product engine; Voyager’s scientific approach and general development progress; the availability or commercial potential of Voyager’s product candidates; the sufficiency of cash resources; and need for additional financing. These statements are also subject to a number of material risks and uncertainties that are described in Voyager’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as updated by its subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Tuesday, February 20th, 2018 Uncategorized Comments Off

$STLHF Provides California Lithium Exploration Update

VANCOUVER, British Columbia, Feb. 20, 2018 — Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSX-V:SLL) (OTCQX:STLHF) (FRA:S5L) is pleased to provide an update of the exploration program that is in full swing at the Company’s California Lithium Properties. The Company and their drilling contractors have now completed six exploration boreholes across the Bristol Dry Lake Project area, and three of the exploration holes have had temporary sampling casing installed so that high quality lithium brine samples can be collected from the extensive lithium brine-bearing aquifers. The temporary PVC casing also allows for down-hole geophysics to be completed to collect additional geological and hydrogeological data. Drilling of an observation well is currently ongoing, and once completed, will allow for robust pumping tests to be performed at the Project. An additional exploration well and observation well are already permitted, and the Company is awaiting final confirmation to allow an additional, deeper exploration borehole to be drilled on Patented claims owned by Tetra Technologies Inc. Detailed lithium brine analyses will be issued once final, representative brine samples have been taken and cross-checked with all QA/QC to ensure quality. All data gathered from the Bristol Dry Lake Project will be used to advance the maiden resource estimate, expected towards the end of Q2 2018.

The Company has also confirmed that a large-scale, detailed gravity geophysical survey is scheduled to be performed on the Cadiz Dry Lake Lithium Property, commencing on February 21^st, 2018. The survey has been designed to tie into historical gravity survey work completed in the Cadiz Dry Lake area by the USGS, and will allow the thickness and extent of the deep infilled basin to be properly defined. Active brine harvesting from relatively shallow wells is ongoing in the Cadiz Dry Lake area, and Standard Lithium’s technical team will commence a full sampling program from this active well field in the next 2-3 weeks.

Quality Assurance

Raymond Spanjers, Certified Professional Geologist (SME No. 3041730), is a qualified person as defined by NI 43-101, and has supervised the preparation of the scientific and technical information that forms the basis for this news release. Mr. Spanjers is not independent of the Company as he is an officer in his role as Vice President, Exploration and Development.

About Standard Lithium Ltd.

Standard’s value creation strategy encompasses acquiring a diverse and highly prospective portfolio of large-scale domestic US brine resources, led by an innovative and results-oriented management team with a strong focus on technical skills. The Company is currently focused on the immediate exploration and development of the Bristol Dry Lake Lithium Project located in the Mojave region of San Bernardino County, California; the location has significant infrastructure in-place, with easy road and rail access, abundant electricity and water sources, and is already permitted for extensive brine extraction and processing activities. The Company is also commencing resource evaluation on up to 33,000 acres of brine leases located in the Smackover Formation.

Standard Lithium is listed on the TSX Venture under the trading symbol “SLL”; quoted on the OTCQX under the symbol “STLHF”; and on the Frankfurt Stock Exchange under the symbol “S5L”. Please visit the Company’s website at www.standardlithium.com.

For further information, contact Anthony Alvaro at (604) 240 4793

On behalf of the Board,

Standard Lithium Ltd.

Robert Mintak, CEO & Director

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target, “plan”, “forecast”, “may”, “schedule” and other similar words or expressions identify forward-looking statements or information. These forward-looking statements or information may relate to future prices of commodities, accuracy of mineral or resource exploration activity, reserves or resources, regulatory or government requirements or approvals, the reliability of third party information, continued access to mineral properties or infrastructure, fluctuations in the market for lithium and its derivatives, changes in exploration costs and government regulation in Canada and the United States, and other factors or information. Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affections such statements and information other than as required by applicable laws, rules and regulations.

Readers are cautioned that a “Qualified Person” (as that term is defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects) has not done sufficient work to specify any mineral resource or reserve on the Properties.

Tuesday, February 20th, 2018 Uncategorized Comments Off

$DJACF Hiku Brands Awarded Prized Retail Cannabis License In Manitoba

Hiku Brands is one of only four proposals selected to operate cannabis retail stores in Manitoba as part of world’s first RFP process for federally legal cannabis retail

TORONTO, Feb. 16, 2018 – Hiku Brands Company Ltd. (“Hiku” or the “Company“) (CSE:HIKU), is pleased to announce that its wholly-owned subsidiary, Tokyo Smoke, with participation by BOBHQ, has been conditionally awarded one of four master retail licenses (the “License“) in Manitoba’s highly competitive Request for Proposal (“RFP“) process for the right to operate retail cannabis stores. The License gives Tokyo Smoke the ability to operate legal retail cannabis stores and an online cannabis sales platform in Manitoba. This represents a significant milestone for Hiku and BOBHQ as one of only four successful entities selected in a highly competitive process.

Hiku is excited to bring its award winning retail experience to Manitoba and Manitoba cannabis consumers. The Company commends the leadership shown by the Province of Manitoba in setting up a competitive, privatized cannabis retail system to ensure the responsible management of cannabis distribution and sales within the province ahead of the anticipated adult-use legalization date of Summer 2018.

“We are honoured to be selected as one of four companies to operate retail cannabis stores in Manitoba“, said Alan Gertner, CEO of Hiku. “This achievement is a validation of our business model and vision of creating an unsurpassed retail experience for cannabis consumers. It is also a tribute to the hard work and dedication of our team and consultants — BOBHQ and 4Front Advisors — who helped us achieve this milestone. We look forward to participating in future licensing processes across the country to grow our national retail footprint and bring our unique retail experience to more Canadians.”

“We are thrilled to have been awarded one of four licenses in our home province of Manitoba alongside our valued partners at Hiku”, said BOBHQ co-founder Robert Ritchot. “We have the utmost confidence in our ability to provide our community with an industry-leading retail experience, while closely adhering to both Provincial and Federal legislation.”

As a retail cannabis organization, Tokyo Smoke will also participate in and contribute to social responsibility programs to provide comprehensive cannabis education to retail cannabis store customers and raise awareness of the social responsibility that comes with adult cannabis use. The Company is fully supportive of the Manitoba government’s clear policy initiatives as it relates to cannabis retail, including, social responsibility, education, protecting children and youth and preventing diversion of product to the black market.

About Hiku
Hiku is focused on building a portfolio of iconic, engaging cannabis brands, immersive retail experiences and handcrafted cannabis production. With a national retail footprint led by Tokyo Smoke, craft cannabis production through DOJA’s ACMPR licensed grow, and Van der Pop’s female-focused educational platforms, Hiku houses an industry-leading portfolio that sets the bar for cannabis brands in Canada.

DOJA Cannabis, Hiku’s wholly-owned subsidiary, is a federally licensed producer of craft cannabis pursuant to the Access to Cannabis for Medical Purposes Regulations (the “ACMPR“). DOJA owns and operates two production facilities in the heart of British Columbia’s Okanagan Valley. The Company operates a network of retail stores selling coffee, clothing and curated accessories, across British Columbia, Alberta and Ontario.

About BOBHQ
BOBHQ, a division of Humble & Fume, is a leading North American distributor of smoke shop and counterculture products with many decades of experience. With retail locations in Manitoba and distribution facilities in Canada and across the U.S., the company is able to efficiently distribute over 10,000 different products to thousands of customers throughout North America and abroad.

Regarding Forward-Looking Information

This news release contains statements that constitute “forward-looking statements”. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Hiku’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur.

Forward-looking statements in this document include the Company’s expectation that adult-use legalization of cannabis will occur in the of Summer 2018. By their nature, forward-looking statements are based on the opinions and estimates of management at the date the information is made, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Hiku is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

The Canadian Securities Exchange has not approved nor disapproved the contents of this news release.

Friday, February 16th, 2018 Uncategorized Comments Off

$CIIX Educates, Bring Awareness to Chinese-speaking Community on Cryptocurrency

February 5, 2018

Despite China’s ban on cryptocurrency, CIIX is positioned to lead the way in cryptocurrency education and awareness for the Chinese-speaking community
Demand for bitcoin continues to rise despite China’s ban on cryptocurrency
Company is committed to the education and growth of cryptocurrency and providing innovative ways of making bitcoin more accessible

ChineseInvestors.com, Inc. (OTCQB: CIIX) is continuing its commitment to cryptocurrency education and awareness for the Chinese-speaking community. Its educational services seek to answer the average person’s curiosity while simultaneously providing skilled investors with up-to-date news on digital currency. Using the Chinese language character sets, CIIX provides analysis and education that is accessible to the Chinese-speaking community worldwide. CIIX provides information on how to purchase bitcoin, real-time market commentary and consulting services, as well as advertising and public relations services.

Cryptocurrency is appealing in that it allows investors to diversify their portfolios. This shift away from traditional investment opportunities brings with it an air of excitement. Bitcoin is being exchanged by investors in unregulated offline platforms in an effort to bypass China’s ban (http://cnw.fm/D3Hxq). The scarcity of bitcoin, and the complexity of mining new coins, is part of the draw. Despite a recent post by China’s Communist Party paper bashing bitcoin and insisting that cryptocurrency is a load of hype, demand has continued to rise (http://cnw.fm/jA6Le).

CIIX is committed to raising awareness and education surrounding bitcoin. The company now hosts a daily broadcast from the NYSE, titled ‘Bitcoin MultiMillionaire’, with the intent of educating Chinese-speaking viewers on the most current news in cryptocurrency. In addition, CIIX is committed to bitcoin growth and has installed a bitcoin ATM in the lobby of its headquarters in San Gabriel, California. The Chinese middle and upper class is growing and looking for new ways to diversify their portfolios. ChineseInvestors.com is ready and able to offer them innovative accessibility to cryptocurrency.

For more information, visit the company’s website at www.ChineseInvestors.com

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Friday, February 16th, 2018 Uncategorized Comments Off

$STLHF Closing of $21.6 million Bought Deal Private Placement of Units

VANCOUVER, British Columbia, Feb. 16, 2018 — Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSX-V:SLL) (OTCQX:STLHF) (FRA:S5L) announced today that it has closed its previously announced bought deal private placement of 10,312,821 units of the Company (the “Units”), at a price of $2.10 per Unit, for aggregate gross proceeds to the Company of $21,656,924, including the issuance and sale of the Underwriters’ (as defined below) option (the “Offering”). Each Unit consists of one common share of the Company and one-half of one common share purchase warrant (each whole common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company (a “Warrant Share”) until February 16, 2020 at an exercise price of $2.60 per Warrant Share, subject to adjustment in certain events. Net proceeds from the Offering will be used for exploration and development activities on the Company’s properties and for general corporate purposes.

The Offering was conducted by a syndicate of underwriters led by Canaccord Genuity Corp., as sole bookrunner and lead underwriter, and including GMP Securities L.P. (the “Underwriters”). In connection with completion of the Offering, the Underwriters received a cash commission of 7.0% and options to acquire a number of Units equal to 7.0% of the Units issued in the Offering until February 16, 2020 at an exercise price of $2.10. The Company paid a further cash commission of 3.0% and issued common shares equal to 3.0% of the Units issued in the Offering to a third-party who assisted in facilitating the Offering.

All securities issued or issuable under the Offering are subject to a statutory hold period lasting four months and one day following the closing of the Offering.

About Standard Lithium Ltd.

Standard Lithium’s value creation strategy encompasses acquiring a diverse and highly prospective portfolio of large-scale domestic brine resources, led by an innovative and results-oriented management team with a strong focus on technical skills. The Company is currently focused on the immediate exploration and development of the Bristol Dry Lake Lithium Project located in the Mojave region of San Bernardino County, California; the location has significant infrastructure in-place, with easy road and rail access, abundant electricity and water sources, and is already permitted for extensive brine extraction and processing activities. The Company is also commencing resource evaluation on up to approximately 33,000 acres of brine leases located in the Smackover Formation.

For further information, contact Anthony Alvaro at (604) 240 4793.

On behalf of the Board,

Standard Lithium Ltd.
Robert Mintak, CEO & Director

The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

This news release may contain certain “Forward-Looking Statements” within the meaning of applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target, “plan”, “forecast”, “may”, “schedule” and other similar words or expressions identify forward-looking statements or information. These forward-looking statements or information may relate to the anticipated use of proceeds of the Offering, future prices of commodities, accuracy of mineral or resource exploration activity, reserves or resources, regulatory or government requirements or approvals, the reliability of third party information, continued access to mineral properties or infrastructure, fluctuations in the market for lithium and its derivatives, changes in exploration costs and government regulation in Canada and the United States, and other factors or information. Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements and information other than as required by applicable laws, rules and regulations.

Friday, February 16th, 2018 Uncategorized Comments Off

$MBRX Breakthrough Discovery of a New Molecule for Cancer Treatment

Cutting Edge Science Suggests New Molecule Is Capable of Shutting Down Tumor Activity

HOUSTON, TX–(February 15, 2018) – Moleculin Biotech, Inc., (NASDAQ: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that, pursuant to its continued collaboration with MD Anderson it has developed and licensed what it believes, based on preclinical testing, is a major breakthrough in its effort to develop a new cancer treatment that selectively kills highly resistant tumors.

“We believe our unique approach to develop immuno-stimulating STAT3 inhibitors just took a major step forward,” commented Walter Klemp, Chairman and CEO of Moleculin. “Our WP1066 portfolio has already resulted in multiple collaborations with some of the most prestigious cancer centers in the world and now this new discovery could dramatically improve our ability to treat a broader range of the most difficult cancers, and especially pancreatic cancer.”

Dr. Don Picker, Moleculin’s Chief Science Officer, explained, “The scientific community recognizes the potential for small molecule immuno-stimulating STAT3 inhibitors to become a game-changer for treating cancer patients. We believe this discovery may not only dramatically improve our ability to develop and deliver such therapies, it may also help support a new mechanistic understanding of oncogenic transcriptional activity. Specifically, we now have preclinical evidence to suggest we are capable of controlling a process known as ‘ubiquitination’ to block the activated form of STAT3, an important oncogenic transcription factor. The study of the role of ubiquitination in cancer is cutting edge science and appears to hold great promise. And, given the desperate lack of treatment options for indications like pancreatic cancer, we believe clinical researchers across the country have been eagerly awaiting a breakthrough like this.”

“In developing our current lead STAT3 inhibitor, WP1066, for brain tumors, we have focused on its oral bioavailability and brain uptake,” continued Dr. Picker, “but at the same time we have continued our quest to expand this portfolio by the creating alternative inhibitors with increased bioavailability and altered tissue and organ distribution that are not affected by first-pass metabolism. The lead molecule resulting from this new discovery is called WP1732 and it not only appears to share the same key mechanistic properties with WP1066, it has markedly different organ distribution and its dramatically increased solubility makes it ideal for administration via standard IV injection. Importantly, preclinical testing has also shown that WP1732’s properties make it a promising candidate for treating pancreatic cancer, one of the most resistant and deadly forms of cancer.”

“So much has happened in the past few months, it’s important to recap where we are,” added Mr. Klemp. “Moleculin has three potential breakthrough disruptive technologies — (1) Annamycin, an anticancer agent that is active against multidrug resistant tumor cells and has been designed to be non-cardio toxic (unlike currently approved drugs in this class), (2) immuno-stimulating STAT3 inhibitors like WP1066 and, now, WP1732, and (3) WP1122, a metabolic inhibitor that has been shown in preclinical testing to effectively block the energy supply required by cancer cells to function and proliferate. Since our IPO in June 2016, we have accelerated to the point of having two drugs, Annamycin and WP1066, beginning clinical trials in the near term.”

Mr. Klemp concluded, “We are now demonstrating the breadth of our drug pipeline and the benefits of collaborating with world-class cancer research centers. In the AML space, we expect patient dosing either in the United States or Poland to begin with Annamycin yet this quarter and we have begun to work with researchers at MD Anderson on using our immuno-stimulating STAT3 inhibitors to target AML as well. A second clinical trial targeting brain tumors with WP1066 should begin dosing within the first half of the year. In Poland, we are about to request a clinical trial authorization for WP1220 for the topical treatment of Cutaneous T-Cell Lymphoma (CTCL), which we expect will become our third clinical trial this year. WP1220 is our patented STAT3 inhibitor designed to be compatible with topical formulations and was selected based on its preclinical activity in CTCL cell lines and based on the need for better topical treatments for CTCL. Additionally, we just announced positive data for WP1122, our glycolysis inhibitor, in a pancreatic cancer mouse model. Along with the newly licensed discovery of WP1732, this sets the course for establishing the base for two more Investigational New Drug (IND) applications over the coming year and positions us as a leader in developing new approaches for pancreatic cancer. Our highly experienced leadership and expanding team is looking forward to sharing more progress on all of this activity as we move forward into 2018.”

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Our clinical stage drugs are Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, a modulator of hard-to-target tumor cell signaling mechanisms intended to attack tumor activity directly while also recruiting the patient’s own immune system. We are also engaged in preclinical development of additional drug candidates, including compounds targeting the metabolism of tumors.

For more information about the Company, please visit http://www.moleculin.com.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of Annamycin, WP1066 and WP1220 to demonstrate safety and efficacy in clinical trials and the timing of the commencement of such trials, and the ability of WP1732 and WP1122 to achieve IND status and to demonstrate safety and efficacy in human patients. These statements relate to future events, future expectations, plans and prospects. Although Moleculin Biotech believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin Biotech has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (“SEC”) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Contacts
Joe Dorame, Robert Blum or Joe Diaz
Lytham Partners, LLC
602-889-9700
mbrx@lythampartners.com

Thursday, February 15th, 2018 Uncategorized Comments Off

$ETST NetworkNewsAudio Audio Press Release on Cannabis Biotech

New York, New York–(Newsfile Corp. – February 15, 2018) – NetworkNewsAudio announces the Audio Press Release (APR) titled “Cannabinoids Lead to Marijuana Biotech Boom,” featuring Earth Science Tech, Inc. (ETST).

To hear the NetworkNewsAudio version, visit: LINK

To read the original editorial, visit: LINK

Earth Science Tech’s CBD work is carried out through its subsidiary Cannabis Therapeutics, Inc. (CTI). The company’s CBD oil is 100 percent natural and organic, catering to the environmental concerns common among cannabis users. It is made using a CO2 liquid extraction process that results in a full-spectrum, high-grade hemp CBD oil that has the highest purity and quality on the market.

To keep it in the lead of the CBD market, Earth Science Tech has created partnerships with other research bodies to produce cutting-edge treatments. It is working with the University of Central Oklahoma and DV Biologics Laboratory on research and development projects to enhance the healthcare benefits of its CBD oil. This has positioned the company to take a leadership role in the development of cannabinoid-based pharmaceutical and nutraceutical products. The company holds a provisional application patent for a CBD product for treating breast and ovarian cancers, taking CBD treatments in bold new directions.

One major focus is integrating the CBD molecule with existing generic drug molecules to create more efficient medications that have fewer side effects than the more common approaches. The company is therefore engaged not only in making cannabinoids useful and available to a wider range of patients, but in creating a better experience for existing patients.

About Earth Science Tech, Inc.

Earth Science Tech has among the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the superior supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research, performed alongside the University of Central Oklahoma and DV Biologics laboratory, demonstrate that we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil. For more information, visit the company’s website at www.EarthScienceTech.com

About NetworkNewsAudio

For more information, visit: www.NetworkNewsAudio.com

About NetworkNewsWire

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.

Forward-Looking Statements

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Thursday, February 15th, 2018 Uncategorized Comments Off

$NETE Achieves Notable Growth, Investments in 2017

February 6, 2018

Net Element is looking forward to continued growth in 2018
2017 held a number of accomplishments, including the company’s strongest balance sheet and a $7.55 million investment
Over the past year, Net Element has produced important product launches in the U.S. and internationally

Net Element, Inc. (NASDAQ: NETE) is looking forward to continual development and delivery of innovative payment solutions in 2018 and beyond. According to a recent press release (http://nnw.fm/8aDOe), last year provided the company with its strongest balance sheet on record. In 2017, Net Element re-focused business initiatives internationally and saw organic growth across all categories. In a news release, CEO Oleg Firer said that the company’s leadership team is very pleased with the progress made and looks “forward to significant accomplishments in 2018 to include the addition of blockchain technology that will act as a framework for an unlimited number of value-added services.” According to Firer, the future looks promising as the company remains focused on the execution of its long-term objective “to create a single, international on-boarding and transaction processing platform across payments ecosystems.”

In 2017, the company received a $7.55 million institutional investment, supporting continued organic growth and ensuring full scalability of its platform, as well as blockchain-focused developments. Deloitte’s 2017 Technology Fast 500™ ranked Net Element as one of the fastest-growing companies in North America. The year before, 2016, South Florida Business Journal ranked Net Element as one of the fastest-growing technology companies. When Hurricane Irma hit, the company was ready and able to support affected Florida SMB merchants with free mobile point-of-sale credit card readers. Net Element works to provide virtually seamless payment solutions and powerful problem-solving expertise to the small to medium enterprises it serves. The $7.55 million investment has put the company in position to continue achieving organic growth as it moves forward with innovative blockchain developments.

The company competes in highly competitive market segments using innovative technology at the core of its products. In 2017, Net Element launched several successful products to better the user experience. The products launched exclusively in the United States included a same-day ACH payment processing solution, a zero-fee processing program for SMB merchants and PayOnline’s support for electronic commerce. In Russia, the company launched Apple Pay support. Additional product launches included loyalty programs for merchants; a payment acceptance module for Telegram, Viber and Facebook; VK instant messenger apps; a comprehensive point-of-sale program during Unified Payments’ 2017 Launch Series at the Northeast Acquirers Association event; and an ISO incubator program for certified resellers of Unified Payments. NETE also expanded payment modules to include Prominent InSales.

Net Element has goals in the United States and internationally. In the U.S., it seeks to grow transactional revenue. By using blockchain technology and Aptito, a cloud-based, restaurant and retail point-of-sale solution, the company aims to grow transactional revenue. Internationally, it leverages an omni-channel platform, delivering flexible offerings to emerging markets.

For more information, visit the company’s website at www.NetElement.com

More from NetworkNewsWire

About NetworkNewsWire

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Thursday, February 15th, 2018 Uncategorized Comments Off

$PBIO Just Might Have the Ideal Drug Delivery Technology for Cannabinoids

February 15, 2018

The tide of cannabis legalization continues to rise
Medical cannabis market on pace to hit $56 billion in seven years
Company’s proprietary technology improves the bioavailability of cannabinoids

For more information, visit the company’s website at www.PressureBioSciences.com

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Thursday, February 15th, 2018 Uncategorized Comments Off

$VSQTF New Merger Sparks Search For Next CryptoKitties and Tron Dogs

The gaming industry has come a long way since the days of plugging quarters into a PAC-MAN or Atari machine in video arcades. Gaming has grown to become the highest grossing entertainment product of all time. That evolution happened incrementally- Xbox gamers started joining online groups and building virtual relationships — forging bonds through love of the game. The stimulus was about tapping into a mental agility- and the reward was reaching the next level of the game.

New games have appeared in the gaming galaxy — CryptoKitties exploded onto the gaming scene in 2017, and on December 2, the high selling cat was sold for 246.9255 ETH ($117,712 USD) on that day. Tron (TRX) Dogs, the kitties’ more masculine counterpart, had soared to a $16 billion market cap in early January.

Blockchain-focused venture builder Victory Square Technologies Inc (OTC:VSQTF) (CSE:VST) (FWB:6F6) is becoming more active in the gaming space, and aims at innovating virtual economies. Leading companies that could potentially move into this direction are Western Union Company (NYSE: WU), HIVE Blockchain Technologies Ltd. (OTC: HVBTF), and HashChain Technology Inc. (OTCQB: HSSHF).

Blockchain-based cryptocurrencies have undoubtedly penetrated the gaming market, and the paradigm shift is now there are more options and new forms of rewards and upgrades for gamers.

The World of Warcraft is the juggernaut of the industry — raking in over $10 billion in revenue. Imagine how much more revenue this multi-player game could earn on in-game purchases with blockchain technology. Blockchain could potentially take gaming from a $108 billion industry to a $trillion industry.

Yesterday, Victory Square Technologies announced the company has acquired 100 percent of all issued and outstanding shares of Vancouver-based mobile games developer V2 Games Inc. for $2 million CAD.

V2 Games started as a game development and publishing studio, and was the first Canadian Company to license the iconic PAC-MAN IP for a mobile game. The company has an operating history of licensing large IPs, including PAC-MAN, Hello Kitty, the NFL and the NBA. Fueled by its success in the mobile gaming market, V2 Games started investing its returns into other companies in the gaming ecosystem.

V2 Games’ portfolio of companies includes Kung Fu Factory, Immersive Tech and Nyan co. In January, V2 Games launched the Future Fund – a $10 million seed fund for gaming ventures. The fund is for strategic investments into the video game vertical, and targets game ventures, esports, as well as start-ups that have a strong use-case for leveraging blockchain within the gaming ecosystem. While the fund will have a global outlook, 50 percent of the fund will be reserved for investments in Canadian video gaming startups.

“Just as we’ve committed to partnering with high quality entrepreneurs and management teams that drive long-term shareholder value, V2 Games supports top tier teams in the gaming industry with a view to unlocking their potential by providing them with seed capital and the necessary strategic expertise needed to scale their gaming ventures,” said Victory Square CEO Shafin Diamond Tejani.

Tejani added that post-acquisition, Victory Square will integrate V2 into the company’s growing portfolio of disruptive technology investments.

Sam Chandola, CEO of V2 Games, said the acquisition is in line with the company’s core competency of identifying early investments in gaming assets, and that it also puts V2 ahead of schedule in its pursuit to be a key strategic investment hub.

This merger marks a meeting of great minds, and surely sets the stage for future disruptive investments as this entrepreneurial team sets its goal on discovering the gaming galaxy’s next Cryptokitties and Tron Dogs.

Comparables:

DMG Blockchain Solutions Inc. (TSX-V: DMGI)

DMG Blockchain Solutions is focused on managing and developing solutions to monetize the blockchain ecosystem. It intends to become a leader in Bitcoin mining, mining as a service (MaaS), forensics, and diversified blockchain platform development. Recently, DMG acquired Blockseer, a U.S.-based company that provides the analytics tools for blockchain data.

HashChain Technology Inc. (OTCQB: HSSHF)

HashChain Technology is a blockchain company focused on mining various types of cryptocurrencies in North America using its proprietary technology. The company has already signed purchase orders for 5,000 mining rigs. Last month, it received another 770 rigs from China.

Western Union Company (NYSE: WU)

Colorado-based Western Union is the world’s largest money transfer service. The company has started trials using Ripple’s enterprise blockchain for its transactions. According to the company, it will continue to explore blockchain applications for its business.

HIVE Blockchain Technologies Ltd. (OTC: HVBTF)

HIVE Blockchain is currently operating as a cryptocurrency mining firm through an established partnership with Genesis Mining Ltd. Recently, HIVE started its Ethereum mining operations in Sweden. The company has raised over $200 million since last September to finance its business.

For a more in-depth look into CSE:VST, view the full report.

Legal Disclaimer/Disclosure:

This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this article should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Baystreet.ca assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this article and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Baystreet.ca has been compensated one thousand eight hundred dollars for its efforts in distributing the Victory Square article. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this article.

Thursday, February 15th, 2018 Uncategorized Comments Off

$DBVT Provides Update on Regulatory Progress for Viaskin Peanut

Montrouge, France, February 14, 2018

DBV Technologies Provides Update on Regulatory Progress for Viaskin Peanut

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) today announced that the U.S. Food and Drug Administration (FDA) has agreed that the available efficacy and safety data for Viaskin Peanut supports the submission of a Biologics License Application (BLA) for the treatment of peanut allergy in children four to 11 years of age.

The FDA provided written responses to the clinical pre-BLA meeting package submitted by the Company, which reflect agreement on the content of the clinical module of the BLA for Viaskin Peanut. DBV remains on track to submit its BLA in the second half of 2018.

“We are pleased with this positive step forward in our progress towards potential approval of Viaskin Peanut, and appreciate the feedback we received from the FDA supporting submission of our BLA,” said Dr. Pierre-Henri Benhamou, Chairman & Chief Executive Officer of DBV Technologies. “There are approximately one million children in the U.S. diagnosed with this life-threatening disease, and we look forward to continue working with the agency to address this urgent unmet medical need.”

About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

Forward Looking Statements
This press release may contain forward-looking statements and estimates, including statements regarding the potential of Viaskin Peanut and the regulatory posture of Viaskin Peanut. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, the products of the Company have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals and the risk that historical clinical results in one patient population may not be predictive of future clinical trial results in different patient populations. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers, the Company’s Securities and Exchange Commission filings and reports, including in the Company’s Annual Report on Form 20-F for the year ended December 31, 2016 and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.

DBV Investor Relations Contact
Sara Blum Sherman
Senior Director, Investor Relations & Strategy
+1 212-271-0740
sara.sherman@dbv-technologies.com

DBV Media Contact
Roberta Di Giorgio
Senior Director, Corporate Communications
+1 917-612-2861
roberta.digiorgio@dbv-technologies.com

Wednesday, February 14th, 2018 Uncategorized Comments Off

$FOSL Could hit $25, Analysts Say

Fossil Group Inc (NASDAQ:FOSL) stock skyrocketed after the company topped revenue and earnings estimates for the fourth quarter. Additionally, its move to become an e-commerce/wearable-tech brand enhanced investor’s confidence in its future fundamentals.

Fossil share price rose almost 67% in early trading on Tuesday; shares briefly hit $17 before retreating to $14 a share.

Solid Q4 Results For Fossil Group Inc

Fossil revenue topped the consensus estimate by $31 million, while earnings exceeded analysts’ estimates by $0.27 per share.

Additionally, the company has achieved several major milestones, aimed at accelerating its strategic objective of moving the revenue base to new channels. The company has been following four key strategic goals:

Driving growth in wearable’s across its portfolio of powerful brands
Leveraging its scale to lower supply chain costs
Increasing its digital capabilities
Continuing the transformation of its business through New World Fossil.

Its business strategies are working; wearable sales doubled to over $300 million in Q4, accounting for 14% of total watch sales. The sales for Michael Kors watches improved in the latest quarter, and Armani watches posted double-digit growth in sales.

Its CEO said, “We introduced a number of new hybrid and display smartwatches across 14 brands and believe the continuation of this effort, combined with the innovation we are introducing across our traditional styles, has us poised for stabilization and growth over time.”

On the other hand, Fossil management substantially expanded its digital presence – allowing the company to generate 31% Y/Y growth in e-commerce sales in the fourth quarter.

>>GNC Holdings: Bullish Bets Soar

The Stock is Set to hit $25, Analysts Say

KeyBanc has lifted FOSL stock price target to $25 from the earlier price target of $15. Several other analysts, including L&F Capital Management and DTF Capital, expect steady growth in FOSL share price.

Overall, investors are admiring the company’s strategy of reducing the cost structure, while moving its business model towards higher growth businesses. Fossil management lowered its expenses by $95 million last year; expecting to reduce operational costs by $200 million by the end of 2018

Wednesday, February 14th, 2018 Uncategorized Comments Off

Uncategorized

Albemarle (NYSE: ALB)

Nemaska Lithium Inc. (TSX: NMX) (OTCQX: NMKEF)

Lithium Americas (TSX: LAC) (NYSE: LAC)

Tesla Inc. (NASDAQ: TSLA)

Comparables:

Solid Q4 Results For Fossil Group Inc

The Stock is Set to hit $25, Analysts Say

TraderPower Featured Companies

Top Small Cap Market News

Recent Posts

Recent Comments

Archives

Categories

Meta